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Abstract 
Background: the liver transplant patient has an extraordinary connection 
with the oncological sphere. On the one hand, an increasingly frequent 
investigation of liver transplantation is the presence of a hepatocellular 
carcinoma, and, on the other hand, the appearance of "de novo neoplasms" 
favored by the state of immunosuppression to which these patients are 
subjected. This close relationship with cancer is a frequent cause of death. The 
immunosuppressant treatment based on calcineurin inhibitor (CNI, tacrolimus, 
cyclosporine), controls the appearance of rejection but favor the appearance 
and proliferation of neoplastic cells by relaxation of the immune tumor 
surveillance. The appearance of mTOR inhibitors (mTORi, sirolimus, 
everolimus) within the immunosuppressive arsenal as non-nephrotoxic agents 
may represent an advance in the tumor control of these patients, since they are 
basically used in the area of oncology as antiproliferative agents. 
   Objectives: 1): To analyze if the use of mTORi in the liver transplant patient 
by HCC reduces the incidence of recurrence and increases survival. 2): To 
analyze whether the use of mTORi in the liver transplant patient with de novo 
neoplasia reduces the incidence of recurrence and increases survival. 
   Methodology: retrospective observational analysis of cases (patients with de 
novo neoplasms or those undergoing hepatic transplantation due to 
immunosuppressed hepatocarcinoma with mTOR inhibitors) and controls 
(immunosuppressed with calcineurin inhibitors), analyzing the rate of 
recurrence and cumulative survival. 
   Patients: 392 patients were selected, analyzing cases and controls in two 
groups: patients transplanted for hepatocellular carcinoma (HCC) and patients 
in whom some de novo neoplasia (NN) appeared in their evolution. 
   Results: In the HCC group, alcohol and tobacco consumption increase the 
incidence of HCC. (Alcohol: p = 0.035, Tobacco: p = 0.67). Vascular and 
capsular invasion and the Edmondson grade reduce survival (Vascular 
invasion: p = 0.00, appearance of the capsule: p = 0.00, Edmondson: p = 0.09). 
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The use of CNI increases the incidence of recurrent HCC (p = 0.025). In 
comparison with the CNI, the mTORi increase the survival of these patients (p 
= 0.05). As for the NN group, alcohol consumption and tobacco consumption 
reduce survival after tumor diagnosis (alcohol: p = 0.02, tobacco: p = 0.001). 
The resection of NN, in comparison with chemotherapy and radiotherapy, 
increases survival (p = 0.00). The tumor stage and TNM is directly related to 
patient survival (p = 0.000). The use of mTORi in the immunosuppressive 
regimen increases the survival of liver transplant patients with de novo 
neoplasia compared to the use of CNI (p = 0.067). 
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Resumen 
   Antecedentes: el paciente trasplantado hepático presenta una 
extraordinaria conexión con la esfera oncológica. Por un lado, una indacación 
cada vez más frecuente de trasplante hepático es la presencia de un 
hepatocarcinoma, y, por otro lado, la aparición de “neoplasias de novo” 
favorecidas por el estado de inmunosupresión al que están sometidos estos 
pacientes. Esta estrecha relación con el cáncer supone una causa frecuente 
de muerte. El tratamiento inmunosupresor basado en anticalcineurínico (CNI; 
tacrolimus, ciclosporina), controlan la aparición de rechazo pero favorecen la 
aparición y proliferación de las células neoplásicas por relajación de la 
vigilancia tumoral inmunitaria. La aparición de inhibidores de mTOR (mTORi; 
sirolimus, everolimus) dentro del arsenal inmunosupresor como agentes no 
nefrotóxicos pueden suponer un avance en el control tumoral de estos 
pacientes, ya que se utilizan básicamente en el área de la oncología como 
agentes antiproliferativos. 
   Objetivos: 1): Analizar si el uso de mTORi en el paciente trasplantado 
hepático por CHC, reduce la incidencia de recidiva y aumenta la supervivencia. 
2): Analizar si el uso de mTORi en el paciente trasplantado hepático con 
neoplasia de novo, reduce la incidencia de recidiva y aumenta la supervivencia. 
   Metodología: análisis observacional retrospectivo de casos (pacientes con 
neoplasias de novo o aquellos sometidos a trasplante hepático por 
hepatocarcinoma inmunodeprimidos con inhibidores de mTOR) y controles 
(inmunodeprimidos con inhibidores de la calcineurina), analizando la tasa de 
recidiva y supervivencia acumulada. 
   Pacientes: Se seleccionaron 392 pacientes, analizando casos y controles 
en dos grupos: pacientes trasplantados por hepatocarcinoma (CHC) y 
pacientes en los que apareció en su evolución alguna neoplasia de novo (NN).  
   Resultado: En el grupo de HCC, el consumo de alcohol y el tabaco 
aumentan la incidencia de HCC. (Alcohol: p = 0.035, Tabaco: p = 0.67). La 
invasión vascular y de la cápsula y el grado de Edmondson reducen la 
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supervivencia (Invasión vascular: p=0.00, apariencia de la cápsula: p=0.00, 
Edmondson: p=0.09). El uso de CNI aumenta la incidencia de HCC recurrente 
(p=0,025). En comparación con la CNI, los mTORi aumentan la supervivencia 
de estos pacientes (p=0.05). En cuanto al grupo NN, el consumo de alcohol y 
el consumo de tabaco reducen la supervivencia tras el diagnóstico del tumor 
(alcohol: p = 0.02, tabaco: p = 0.001). La resección de la NN, en comparación 
con la quimioterapia y la radioterapia aumentan la supervivencia (p = 0,00). El 
estadío tumoral y TNM se relaciona directamente con la supervivencia del 
paciente (p = 0,000). El uso de mTORi en el esquema inmunosupresor 
aumenta la supervivencia de los pacientes trasplantados hepáticos con  
neoplasia de novo en comparación con el uso de CNI (p = 0.067). 
   Conclusiones: El tabaco y el alcohol reducen la supervivencia de los 
pacientes después del TOH en el HCC y la neoplasia de novo. La invasión 
vascular y capsular y grados avanzados de Edmondson reducen la 
supervivencia de los pacientes trasplantados debido a HCC. La 
inmunosupresión con mTORi, especialmente el everolimus, aumenta la 
supervivencia de los pacientes después del TOH en el HCC en comparación 
con la CNI. Para el cáncer sólido, la resección aumenta la supervivencia de los 
pacientes con TOH con neoplasia de novo en comparación con quimioterapia 
/ radioterapia. TNM y el estadio tumoral son buenos predictores de 
supervivencia. La inmunosupresión mTORi, especialmente everolimus, 
aumenta la supervivencia de los pacientes después del TOH en la neoplasia 
de novo en comparación con la CNI, sobre todo en el cáncer ORL, cáncer de 
pulmón, síndrome linfoproliferativo, cáncer digestivo, cáncer de mama y cáncer 
urinario. Este beneficio de mTORi no se puede aplicar al cáncer de piel ni al 
cáncer hepatobiliopancreático. La monoterapia con MMF también aumenta la 
supervivencia en ORL y cáncer de mama 
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1. INTRODUCTION 
 
1.1.  History of liver transplantation 
 
        Liver transplantation (LT) is considered to be the treatment used in patients with 
acute or chronic liver disease when other alternative therapy has been exhausted and 
it is the best treatment for end-stage chronic liver disease and is associated with a one-
year survival rate that ranges from 78% to 85%1.  
       
        The research possibility of LT began in the 1960s. In 1955, Dr. Welch was the first to 
describe liver transplantation as a treatment and proposed ectopic liver transplantation 
in the abdominal cavity. However, modern liver transplantation is orthotopic liver 
transplant (OLT), which consists of excision of the diseased liver followed by placement 
in the same anatomical location of a healthy liver from an organ donor, constituted by 
grafting the entire or a part of a liver2. A few later, in 1963, Starzl et al attempted the 
first human LT in the world, the patient was a 3-year-old boy with biliary atresia, who 
died during surgery due to coagulation disorder and uncontrolled bleeding3,4. Especially, 
using the same immunosuppressive regimen, at the University of Cambridge, United 
Kingdom, 138 cases of OLT were performed between 1968 and 1984, and the results 
were so disappointing5,6,7. 
 
   In 1990, Starzl et al.8. reported the first use of the new tacrolimus as 
imunosupressant agent in patients submitted to liver transplantation who suffered a 
rejection even using conventional immunosuppressive treatment. Tacrolimus, which is 
similar to CsA but with greater potency. The success of cyclosporine conversion by 
tracrolimus in these patients and by showing it safety and effectiveness of rejection 
control, lots of new clinical studies were conducted with using tacrolimus as the main 
immunosuppressor in liver transplantation8910. Until then, the CNIs (Cyclosporine A and 
Tacmolimus) had been the basis immunosuppressor in OLT. At the end of the 1990s, 
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a new purine synthesis inhibitor was introduced, mycophenolate mofetil (MMF), which 
was presented as a more selective alternative and with greater immunosuppressive 
capacity than azathioprine (AZA). 
 
   In fact, CNIs presents nephrotoxic effects, which are an important source of 
mortality in OLT. Almost 20% of OLT recipients have chronic renal failure after 5 years 
of the transplantation11. Everolimus (EVE) and Sirolimus (SRL), two new 
immunosuppressant of the mammalian Target Of Rapamycin Inhibitor (mTORi), could 
potentially satisfy this adverse effect. The chief advantage sirolimus has over 
calcineurin inhibitors is its low toxicity toward kidneys. Transplant patients maintained 
on calcineurin inhibitors long-term tend to develop impaired kidney function or even 
chronic renal failure; this can be avoided by using sirolimus instead. It is particularly 
advantageous in patients with kidney transplants for hemolytic-uremic syndrome, the 
SRL was approved by the Food Drug Administration (FDA), USA, for kidney 
transplantation, because it has ability to protect kidney function1213. And in the year 
2010, the EVE was approved by the FDA being used together with TAC, and reduced 
dose of TAC and steroid in the OLT recipients to decrease the nephrotoxicity of the 
CNIs. The SRL has been used in several OLT centers in the world for prophylaxis and 
to decrease the nephrotoxicity of CNIs. 
 
 
   In Europe, the OLT was widely applied in the 1980s, where the countries that made 
their first OLT succeeded. (Figure 1.1) According to the information of the European 
Liver Transplant Registry (ELTR), until the present time, 174 transplant centers from 
32 European countries are participating to ELTR. By comparison with the official data 
Transplant Observatory, More than 98% of European liver transplantation’s data are 
continuously updated, analyzed and published by ELTR.  
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Fig.1.1: Evolution of 93,634 LTs performed in Europe since May 1968.  
 
Arrows indicate the year the first LT was performed in indicated countries. This 
decrease is owed to the fact that some centers did not yet send their updating further 
to the recent changes of the questionnaire. 
In Spain, the first OLT was successfully carried out in 1984 in Barcelona. The annual 
number of OLT performed has progressively increased, reaching 1,000 cases per year 
in the last 10 years. The high activity of OLT is associated with a high rate of liver 
donation. Spain has an index of 14 donors per million inhabitants, which is the highest, 
not only in Europe but also in the world. 
For now, almost 50 years after the first OLT, the survival rates of 1 and 5 years are 
85% and 73%, respectively14. This success is related to advances in surgical technique, 
progress in immunosuppression, progress in graft conservation and anesthetic 
technique, and advances in perioperative care. 
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1.2.  Indication and contraindication of liver transplant 
 
1.2.1. Indication of liver transplant 
 
The principal objectives of OLT are to prolong survival and improve the quality of 
life of the patient, while also optimizing the use of available organs15. In general, OLT 
is recommended in those patients in whom a possibility of survival without OLT less 
than or equal to 90% per year is expected, regardless of the etiology of the disease 
that motivates the OLT.  
 
Recipient candidates must meet three conditions: 
 
l Have incurable and deadly disease in the short term. 
l No contraindication 
l Be able to understand and accept what the transplant represents as well as 
the servitude that it entails. 
 
It is understood as an incurable and deadly disease in the short-term that is 
progressive and irreversible, with little or no response to treatment, with a poor quality 
of life and that presents a low percentage of survival per year. 
 
List of liver transplant treatment diseases. 
 
1. Chronic liver diseases 
 
l Chokes 
    Primary biliary cirrhosis 
Secondary Biliary Cirrhosis 
Primary Sclerosing Cholangitis 
Biliary Atresia 
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Caroli's disease 
Family Cholestatic Syndromes 
 
l Parenchymatous 
 
Virus-related liver Cirrhosis (B, C, D, ...) 
Alcoholic Liver Cirrhosis  
Drug-induced Liver Cirrhosis 
Autoimmune Liver Cirrhosis 
Cryptogenic Cirrhosis 
 
l Vascular disease 
    Venous-Occlusive Disease 
Budd-Chiari Syndrome 
Congenital Hepatic Fibrosis  
 
2. Liver neoplastic diseases 
 
                Hepatocellular carcinoma 
Metastasis of Neuroendocrine Tumors 
Cholangiocarcinoma 
Other Liver Neoplasms 
 
3. Acute or subacute liver failure 
 
                Acute severe liver failure secondary to virus (A, B, C, D, ...)  
Acute severe hepatic insufficiency due to drugs 
Reye's syndrome 
Cryptogenetics 
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4. Metabolic and genetic diseases 
 
                Organic Aciduria 
Familial hereditary amyloidosis 
Alpha-1 antitrypsin deficiency 
Enzymatic deficiencies in the Urea cycles 
Deficiencies of coagulation factors 
Wilson's disease 
Galactosemia 
Glycogenosis Storage Type I and IV 
Hemochromatosis 
Hemophilia A and B 
Homozygous type II hyperlipoproteinemia 
Protoporphyria 
Tyrosinemia 
Crigler-Najjar syndrome type I 
Sanfilippo syndrome 
 
 
 
Liver neoplastic diseases 
 
   Hepatocellular carcinoma(HCC): is a primary malignancy of the liver and occurs 
predominantly in patients with underlying chronic liver disease and cirrhosis. most OLT 
centers agree to use the Milan Criteria, which consist of patients with a single tumor 
less than or equal to 5 cm, or having a maximum of 3 nodules, all of which are less 
than or equal to 3 cm in diameter; regardless of the Child-Pugh stage, formally 
excluding patients with extrahepatic extension, multicentric tumors and / or 
macroscopic vascular invasion. 
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Fig 1.2 The processing of Hepatocellular carcinoma 
 
   Cholangiocarcinoma: due to the high rate of recurrence after OLT, traditionally it 
is not considered an indication of OLT, however, some researchers have suggested 
that a standard protocol involving external beam and endoluminal radiation and 
systemic chemotherapy, with lymphadenectomy, may be suitable candidates for OLT16. 
 
   Fibrolamellar carcinoma and Neuroendocrine tumors metastatic to the liver: 
(gastrinoma, insulinomas, glucagonomas, somatostatinoma and carcinoid tumors): 
they usually settle on the healthy liver. If these tumors are very extensive and the 
functional capacity of the liver is damaged after resection, it will be indicated OLT. The 
recipients should be well selected: young people with massive liver metastases and 
resected primary tumor, in which the symptoms produced by the metastases are not 
controlled with medical treatment; OLT in these cases is more a palliative treatment 
than a cure, due to the high rate of recurrences. 
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1.2.2. Liver transplant procedure 
 
   In patients with chronic liver disease is evaluated mainly with models that predict 
survival in the absence of transplantation. 
 
There are two prognostic models to evaluate the survival of patients with chronic 
end-stage liver disease: the Child-Pugh index and the MELD score (Model for End-
stage Liver Disease). 
 
 
The Child-Pugh index 
 
   This most commonly used prognostic index consists of 5 variables, of which 3 
reflect liver function (albumin, bilirubin and prothrombin time) and 2 refer to 
complications of the disease (ascites and encephalopathy). (Table 1.1-2) 
 
 
 Table 1.1: The score employs five clinical measures of liver disease. Each measure 
is scored 1-3, with 3 indicating most severe derangement 
Table 1.2: Chronic liver disease is 
classified into Child-Pugh class A to C 
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   The total score of 5-6 is considered grade A (well compensated disease); 7-9 is 
grade B (significant functional commitment); and 10-15 is grade C (decompensated 
disease). These grades correlate with a patient's survival at 1 or 2 years. 
 
   The Child Pugh index is very easy to determine, but there are drawbacks. Such are 
that it has not been obtained in multivariate analysis; the assessment of the degree of 
ascites and encephalopathy is subjective; It does not discriminate when the disease is 
very advanced since it has fixed limits for each variable. Despite its drawbacks, it is 
still used to assess the indication for liver transplantation, which is considered indicated 
in Child B and C patients. 
 
 
MELD Score 
 
   MELD (Model for End-stage Liver Disease) was originally developed at the Mayo 
Clinic by Dr. Patrick Kamath, and at that point it was called the "Mayo End-stage Liver 
Disease" score. The MELD Score is based on statistical formulas for predicting the risk 
of death in a short period of time (3 months). 
 
   The MELD is calculated from laboratory parameters: 
 
l Bilirubin 
l INR (international normalized ratio) of prothrombin. 
l Creatinine 
    
The MELD value is calculated with a formula based on Neperian logarithms of the 
mentioned parameters: 
 
MELD = 3.78 × ln [serum bilirubin (mg / dL)] + 11.2 × ln [INR] + 9.57 × 
ln[serum creatinine (mg / dL)] + 6.43 
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   The result is multiplied by 10 and rounded to the nearest whole number. The value 
ranges from 6 to 40, in direct proportion to the severity of the disease. 
 
   The MELD model includes the impact of the variations of the evaluation of the 
components analysis in the laboratory, a lack of recognition of the differences between 
the creatinine in male and female and a potential disadvantage in certain groups of 
receptors, such as those with hyponatremia or those with primary sclerosing 
cholangitis1718. Encephalopathy, tumors and metabolic diseases are risk factors not 
correlated with the MELD, and it would be quite difficult to determine the priority of a 
patient with cirrhosis related complications and a low MELD score19. MELD is used in 
the age of patients older than 12 years. 
 
   The best way to use of MELD in the OLT is as an index to prioritize the patients on 
the waiting list and obtain a fair distribution of the organs obtained. A Child-Pugh score 
greater than 7 (stages B and C), or an MELD score greater than 15, and that is the 
indication for a transplantation. 
 
   However, there are circumstances in some patients in which survival decreases 
drastically, which are either should be deterioration of quality of life (like intractable 
pruritus), or because of a greater complication (such as ascites, encephalopathy, 
refractory digestive bleeding from portal hypertension, hepatorenal syndrome, 
spontaneous bacterial peritonitis). 
 
In fact, the number of donor livers is not sufficient for the candidates of the recipient, 
and the number of patients on the waiting list is increasing, with the consequent 
increase in mortality on the waiting list. Some researchers suggest that the allocation 
of organ resources should be based primarily on the access of cadaveric donor organs 
to those recipients whose quality of life is unacceptable but without terminal disease, 
such as those with intractable pruritus, polycystic hepatis or intractable 
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encephalopathy18. It is necessary to choose well both the donors and the recipients, 
optimize the candidates and determine the appropriate time for the transplant, in order 
to obtain the best possible performance of the organs transplantation. 
 
 
1.3. Surgical technique of liver transplantation 
 
 
   There are three steps of the surgical OLT of recipient: 1. Total hepatectomy; 2. 
Liver implant (vascular and biliary reconstruction); 3. Hemostasis and abdominal 
closure. The traditional technique "veno-venous bypass" was replaced by the 
technique "piggyback", which is not necessary to replace the vena cava, and make the 
hepatectomy with preservation of native retrohepatic vena cava. The ‘piggy-back’ 
technique with temporary portocaval shunt allows one to choose the order of graft 
revascularization. We prefer to do the portal anastomosis first and then the arterial 
anastomosis 20,21. 
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Figure 1.3. The piggyback technique for OLT. Diagram shows the confluence of donor hepatic 
veins that are anastomosed to the recipient suprahepatic IVC. End-to-end hepatic artery 
anastomosis, common bile duct anastomosis, and anastomosis of the donor and recipient 
portal veins are performed, although the exact technique may vary from case to case 
 
   The "piggyback" technique of liver transplantation had been described by Calne et 
al. in 1968 and had been routine used in clinical by Tzakis 20 years later22. The 
character is keeping the continuity of the vena cava of the recipient to implant in it a 
segment of the vena cava of the graft that contains the ostia of the hepatic veins. The 
technique offers the advantage of this technique are that they contain a reduction in 
the risk of stenosis, technical failures associated with the fabrication of two 
anastomoses with IVC, both reduction in the time of operation and bleeding23. 
 
   In the technique, the suprahepatic veins are sectioned intrahepatic, in order to gain 
the largest possible segment of vein to anastomosis. In general, the common trunk of 
the middle and left hepatic veins are very short, so for the anastomosis of the 
 35 
suprahepatic cava easier, the anastomosis area of the vena cava must be prepared. 
During the liver removing, The impermeability of the stump of the infrahepatic cava is 
ensured by obliterating the implantation holes of the caudate lobe veins, sectioned222425. 
 
 
1.4. Complication of liver transplantation 
 
 
   Liver transplantation (LT) is widely accepted as an effective therapeutic modality 
for a variety of irreversible acute and chronic liver disease. But for the patient follow-
up with OLT, there are several complication frequent in postoperative immediately and 
the long-term. As we know, LT is the treatment complicated, any complication is related 
to the mortality of the OLT26.(Tab.1.3) 
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Tab.1.3 Complication of liver transplantation 
 
1.4.1. Complication postoperative immediately 
 
   Immediate postoperative complication 
 
l Postoperative hemorrhage 
 
   It happens mainly during the first 24-48 h after completion of the OLT, with a 
variable prevalence that, in some series, has reached 20%26. Preexisting 
coagulopathy, significant hemorrhage during surgery, imperfect hemostasis and/or 
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immediate poor synthetic function are some of the factors associated with this 
complication. It has been considered a complication and a major problem, and due to 
its severity, up to 12% of the causes of post-transplant mortality have been reached 
in some series2627. 
 
l Liver graft dysfunction 
 
   The transplanted liver can have a normal postoperative course, manifested by 
progressive decrease of transaminases, increase of factor V, prothrombin and 
platelets, control of acidosis, normalization of ammonium, good biliary production, and 
absence of encephalopathy. Dysfunction of the graft may occur in the immediate 
postoperative period or late during the follow-up of the patient. The reason of early 
dysfunction of the graft can be: 1. problems of the graft itself (primary 
dysfunction/malfunction, nonspecific cholestatic syndrome, rejection), 2. complications 
of the surgical technique [vascular (arterial, portal thrombosis, poor drainage of the 
suprahepatic veins), or biliary], and 3. other causes such as drugrelated liver toxicity. 
Primary graft failure is defined as the clinical situation in which there is poor liver 
function to maintain the individual’s life leading to death of the patient or 
retransplantation during the first seven postoperative days. It constitutes between 20 
and 30% of the causes of retransplantation. The mortality of the primary dysfunction 
of graft without retransplantation approaches 80% of the patients, reducing between 
30% and 50% after performing the retransplant2628. It is one of the most serious 
situations in the early post-transplant setting. The exact cause of this severe 
complication is unknown, although there are some of factors conditions: donor age, 
hemodynamic instability, suboptimal donors, cold ischemia time, reperfusion damage 
and the temperature of the preservation solution262729. 
 
l Arterial complication 
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This complications including thrombosis and stenosis of the hepatic artery, which 
cause high morbidity and mortality when they cause severe graft dysfunction. 
Particularly the thrombosis of the hepatic artery (prevalence ranging from 1.5 to 25%) 
are the most frequent ones. The most frequent cause including poor arterial flow, 
increased sinusoidal resistance, preservation injury, stenosis of the anastomosis and 
a state of hypercoagulability26273031. It usually manifests as a sudden and progressive 
deterioration of liver function, unlike primary graft dysfunction, it occurs after a 
variable period of normal hepatic function. 
 
l Portal vein complication 
 
   Portal vein thrombosis is an infrequent complication with an overall prevalence of 
2-3%. It is related to pre-transplantation portal thrombosis, splenectomy, and prior 
portal hypertension surgery. The most frequent cause are technical errors related to 
venous redundancy and torsion and / or stenosis of the anastomosis. Clinically, it has 
been classified as early form(in the first week of the postoperative period) and late 
form(as of the first week). The clinical picture is dominated by symptoms/signs of 
hepatic failure in the early form; and in the late form, the typical presentation was 
manifested portal hypertension, obviously, it is also accompanied by ascites, 
esophagogastric varices and other symptoms2631. 
 
l Caval vein complication  
 
   It is uncommon and rare complication following liver transplantation “thrombosis of 
the vena cava” with an reported incidence of less than 3%. The main risk factor leading 
to caval anastomosis complications is represented by technical errors in the 
connection of caval anastomoses, and usually realized with stenosis anastomosis. 
Clinical presentation ranges from hepatomegaly, ascites, Budd-Chiari syndrome, lower 
limb edema, liver and renal failure to hypotension leading to allograft loss and 
multiorgan failure31. 
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l Biliary complication  
 
Anastomotic leaks and Biliary strictures stenosis are the very frequency in Biliary 
complication after liver transplantation. With an overall incidence of 5% to 25%32. The 
most common is biliary strictures or called biliary stenosis. Biliary strictures usually can 
be divided into two categories and they are anastomotic strictures and non-
anastomotic strictures3233. Anastomotic strictures usually involve the anastomotic site, 
is more commonly associated with biliary reconstruction by hepaticojejunostomy and 
the main cause responsible can be inadequate anastomoses. The mechanism of non-
anastomotic strictures remains unclear, but it is often related to ischemic events. It has 
a worse prognosis and a significant proportion of patients who require re-
transplantation3334. 
 
As we know, the rejection after liver transplantation can be divided acute rejection 
and chronic rejection. Due to chronic rejection belongs to the complication long-term, 
it will be introduce sooner. 
 
l Acute rejection  
 
   The acute cellular rejection (ACR) as the frequency rejection after the liver 
transplantation, and showed incidence of 10-30% in recipients during the first month 
after liver transplantation35. ACR is generally associated with the high-level of hepatic 
enzymes (such as: serum aminotransferases, alkaline phosphatase, gamma-glutamyl 
transpeptidase) and/or bilirubin, especially the gamma-glutamyl transpeptidase (GGT). 
Moreover, for the younger patient (age<40 years) and the recipient of LT without renal 
dysfunction, have the ACR with high possible. But it just can be achieved only with 
histologic analysis of a liver biopsy353637. 
 
l Infection complication  
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Infections continue to be one of the main complications that can contribute to the 
recipient’s death during the first year26. There are series source of the infecting, such 
as the donor organ, transfused blood products and the reactivation of previous 
infection et.al. The most common is the bacterial infections. For the viral infections, the 
source of infecting are cytomegalovirus, Epstein-Barr virus, herpesvirus, hepatitis-B 
and hepatitis-C virus. Without doubt, Fungal also is one of the source of infecting. But 
the incidence of fungal is not high, most of these episodes were caused by Candida or 
Aspergillus3839. 
 
l Respiratory complication  
 
The lung is one mainly organ, in order of frequency, that presents greater infectious 
problems in the immediate postoperative period of OLT. The complications such as 
pneumonia and acute respiratory distress syndrome (ARDS) are associated with 
higher mortality rates despite advanced diagnosis and treatment options. Among those 
with pneumonia and acute respiratory failure, mortality rates were 43.75% and 50%, 
respectively40. Pulmonary effusion also occurs frequently with the mortality rates were 
35.7%, in most cases, caused by intraoperative diaphragmatic manipulation. 
Pulmonary effusion has associated with the higher MELD scores. On the other hand, 
Several preoperative factors combined with a high MELD increase the incidence of 
respiratory failure postoperative, such factors as: perioperative blood transfusion, fluid 
retention, severe restrictive lung patterns, and muscle atrophy related to poor 
nutritional status41. 
 
l Neurological complication  
 
The neurological complications in the OLT are frequent, during the postoperative 
period varies widely from 10 to 42%. The most common CNS complications are 
confusion, seizures, posterior leuco-encephalopathy syndrome and the neurotoxic 
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side-effects of immunosuppressive drugs. Neurological complications are a significant 
cause of morbidity and mortality in patients who undergo liver transplantation, which 
in some series reach a mortality rate is close to 50%. They may happened immediately 
after the operation of OLT or later (a month, three o four months)424344.  
 
 
 
 
Long-term complication 
 
l Chronic rejection 
 
Pathogenesis of CR is not well characterized. The pathogenesis of CR is 
multifactorial and includes vascular occlusion, antibodies and cell mediated pathways. 
Pathophysiology of CR is not entirely clear but immune mechanisms are involved as 
changes of CR does not appear in isografts and sometimes it is extension and result 
of ACR35. With the improvement in immunosuppression regimen, it has been achieved 
to reduce the frequency of episodes of acute rejection, as well as the consequent 
beneficial effect on CR control. In some series, chronic rejection currently occurs in 
less than 5% of transplants45.  
 
l Renal dysfunction 
 
Renal dysfunction (acute o chronic) is one important complication after LT, and it 
occurs in 17-95% of patients46. The alteration of renal function can affect directly 
morbidity and mortality. There are approximate 10-20% patients after LT occur renal 
dysfunction in the medium or long-term. It is close to 20% that the patients occur 
chronic renal dysfunction after OLT 5-10 years47. Some research present many 
preoperative factors may favour the occurrence of renal dysfunction after OLT, such 
as preoperative renal dysfunction, hepatorenal syndrome (HRS), pre-OLT low serum 
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albumin level, hypovolemia, ascites, concomitant chronic diseases leading to kidney 
injury (diabetes mellitus, hypertension), hepatitis C, Child-Pugh score, Meld score and 
the use of Calcineurin inhibitors (CNI)46.  
 
l Arterial hypertension 
 
Arterial hypertension (AHT) is a frequent complication in liver transplant recipients. 
The incidence is between 50-70% in the first months post-transplantation but 
decreases thereafter probably due to the reduction of the immunosuppressive doses26. 
One of the most important factors in OLT is the administration of CNI. Steroids also 
play an important role and their withdrawal is associated with improved blood pressure. 
The incidence of hypertension with tacrolimus treatment is lower and later than 
cyclosporine. It seems that the intensity of vasoconstrictive action mechanisms and / 
or renal retention of tacrolimus sodium is lower than that of ciclosporin2648. 
 
l Diabetes Mellitus 
 
A variable percentage of patients, 10-33% will develop diabetes mellitus following 
transplantation (de novo DM). Some patients, de novo DM resolves a few months after 
the transplantation, But in other hand, it will be permanent. The prevalence depends 
on the time elapsed since transplantation and particularly on the immunosuppressive 
drugs2649. 
 
l Malignancy 
 
De novo malignancy developing after transplantation constitutes a well-known 
complication of organ transplantation, 5-15% of patients who receive a solid organ 
transplant develop a de novo tumor, with a prevalence of cancer being between 3-16%, 
double times higher than the normal population5051. It has been considered second 
cause of death in the long-term of patients after liver transplantation52. The cumulative 
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incidence rate for all de novo malignancies was 1.3% at 1 year, 7.2% at 3 years, 11.7% 
at 5 years, 17.9% at 8 years and 24.8% at 10 years53. 
 
l Cardiovascular complications 
 
Cardiovascular diseases have become the main cause of mortality after OLT. Early 
cardiac complications are relatively frequent, and have been related with patients who 
have cardiovascular disorders in pre-transplantation, such as coronary artery disease 
(CAD), cirrhotic cardiomyopathy (CCM), and structural heart disease54. The factors of 
risk post-transplantation include advanced age, use CNI and undetected coronary 
disease. 
 
 
1.5. BASIC NOTIONS OF ONCOLOGY  
 
Liver cancer, also known as hepatic cancer and primary hepatic cancer, is cancer 
that starts in the liver. The most common liver cancer, accounting for approximately 
90% of all primary liver cancers, is hepatocellular carcinoma (HCC), and is the most 
common cause of death in people with cirrhosis. 
 
1.5.1. Hepatocellular carcinoma (HCC)  
 
 
HCC is now the third leading cause of cancer deaths worldwide, and the morbidity 
is increasing every year. Ranges from 500,000 to 1 million and with a number of 
deaths between 600,000 and 700,000 per year55. The incidence of HCC is highest in 
Asia and Africa, intermediate in Japan and European countries in the Mediterranean 
area, and lower in northern Europe and the USA. That means there are differences 
risk factors and pathogenesis among the different countries. 
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   HCC related with cirrhosis of liver, it mostly occur in cirrhosis patients. So, the risk 
factors include factors which cause chronic liver disease that may lead to cirrhosis.  
 
There are many factors well- known to lead cirrhosis or / and hepatocellular 
carcinoma such as: Chronic viral hepatitis (Viral hepatitis B and C), Alcoholic 
ingestion, Aflatoxin, Iron overload state, Diabetes mellitus, Wilson’s disease, 
Hemophilia56. 
 
   The diagnosis of suspicion is usually made by imaging tests. The objective of 
these tests is the screening of high risk patients, the identification of small lesions, 
the differential diagnosis between space occupying lesions and the selection of the 
appropriate treatment for each patient. If want to know the development and the 
situation of HCC, Biopsy has been necessary.  
 
Staging looks at the size of the cancer (tumour) and whether it has spread 
anywhere else in the body. There are different staging systems doctors can use for 
liver cancer. The TNM staging system is one of these. TNM stands for Tumour (the 
size of the primary tumour), Node (whether the cancer has spread to the lymph 
nodes), Metastasis(whether the cancer has spread to another part of the body).  
 
Stage T normally from 1 to 4, however, Tx and T0 have special significant:  
    
Tx: Primary tumor cannot be assessed 
 
T0: No evidence of primary tumor 
 
T1: Solitary tumor ≤ 2 cm or > 2 cm without vascular invasion 
 
T1a: Solitary tumor ≤ 2 cm (with or without vascular invasion) 
 45 
 
T1b: Solitary tumor > 2 cm without vascular invasion 
 
T2: Solitary tumor > 2 cm with vascular invasion or multiple tumors, none >. 5 cm 
 
T3: Multiple tumors, at least one of which is > 5 cm 
 
T4: Tumor involves a major branch of the portal vein or hepatic vein or tumor directly 
invades adjacent organs other than the gallbladder or tumor perforates the visceral 
peritoneum 
 
Stage N are from X to 1: 
 
NX: Regional lymph nodes cannot be assessed 
 
N0: No regional lymph node metastasis 
 
N1: Regional lymph node metastasis 
 
Stage M: 
 
M0: No distant metastasis 
 
M1: Distant metastasis 
 
According to stage TNM, there is a other stage based on TNM. Clinically, usually 
use the stages above mentions.(Tab. 1.4) 
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Tab. 1.4: Stage I-IV of hepatocellular carcinoma  
 
Unfortunately, the diagnosis of HCC is often made with advanced disease when 
patients have become symptomatic and have some degree of liver impairment56. 
Treatment of hepatocellular carcinoma varies by the stage of disease, a person's 
likelihood to tolerate surgery, and availability of liver transplant:  
 
Partial hepatectomy: when the cancer is limited in one or more tumour in the same 
segment of liver, surgically removing the malignant cells may be curative. This may be 
accomplished by resection the affected portion of the liver or in some cases by 
orthotopic liver transplantation of the entire organ. 
 
   "Downstaging" therapy: for the patient with moderately advanced disease and 
limited in liver. But the disease is too advanced to qualify for partial hepatectomy. The 
patient may be treated by targeted therapies in order to reduce the size or number of 
active tumors, with the goal for satisfy conditions of liver transplant after this treatment. 
 
   Liver transplantation: for limited disease which qualifies for potential liver 
transplantation, the patient satisfy the conditions of Lt and in the waiting list of LT. 
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   Palliative treatment: for end-stage of disease, including spread of cancer beyond 
the liver or in persons who may not tolerate surgery, the objective of treatment 
decrease symptoms of disease and prolong the time of survival. 
 
   Loco-regional therapy refers to any one of several minimally-invasive treatment 
techniques to focally target HCC within the liver. These procedures are alternatives to 
surgery, and may be considered in combination with other strategies, such as a later 
liver transplantation5758. 
 
In the year 2004-05, the media of survival rate is 47-49%, with the development of 
diagnostic and the technique, the survival rate of patients who receive the treatment 
increased Although changes in survival rates for cases with distant HCC were less 
pronounced, patients reporting treatment had higher survival rates59. 
 
 
1.5.2. Lung cancer 
 
 
   Lung cancer, also named lung carcinoma, is a malignant lung tumor characterized 
by uncontrolled cell growth in tissues of the lung. These abnormal cells do not carry 
out the functions of normal lung cells and do not develop into healthy lung tissue and 
this growth can spread beyond the lung by the process of metastasis into nearby tissue 
or other parts of the body. As they grow, the abnormal cells can form tumors and 
interfere with the functioning of the lung, which provides oxygen to the body via the 
blood. 
 
   There are several factors caused lung cancer, such as smoking (Tobacco, 
Marihuana and passive smoking), Radon gas, Asbestos, Air pollution, Genetics and 
others causes (ionizing radiantion, toxic gases et. al.).  
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   The mainly way to diagnosis lung cancer is chest radiograph, obviously, there are 
some others technique can help us to discriminate lung cancer, like CT image and 
biopsy. Same to HCC, in the TNM stage, T means size of primary tumor, N means 
node and M means metastasis to other organ60. 
 
Stage TNM: 
 
   Tx :  Tumor cells present in sputum or bronchial washing, but tumor not seen with 
imaging or bronchoscopy 
T0 :  No evidence of primary tumor 
Tis :  Carcinoma in situ 
T1 :  Tumor size less than or equal to 3 cm across, surrounded by lung or 
visceral pleura, without invasion proximal to the lobar bronchus 
T1mi : Minimally invasive adenocarcinoma 
T1a : Tumor size ≤ 1 cm 
T1b : Tumor size > 1 cm, but ≤ 2 cm 
T1c : Tumor size > 2 cm but ≤ 3 cm 
T2 : Any of: Tumor size> 3 cm but ≤ 5 cm; Involvement of the main bronchus but 
not the carina; Invasion of visceral pleura; Atelectasis or obstructive pneumonitis 
extending to the hilum 
T2a : Tumor size > 3 cm but ≤ 4 cm 
T2b : Tumor size > 4 cm but ≤ 5 cm 
T3 : Any of: Tumor size > 5 cm but ≤ 7 cm; Invasion into the chest wall, phrenic 
nerve, or parietal pericardium; Separate tumor nodule in the same lobe 
T4 : Any of: Tumor size > 7 cm; Invasion of the diaphragm, mediastinum, heart, 
great vessels, trachea, carina, recurrent laryngeal nerve, esophagus, or vertebral body 
or Separate tumor nodule in a different lobe of the same lung 
 
   NX : Regional lymph nodes cannot be assessed 
N0 : No regional lymph node metastasis 
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N1 : Metastasis to ipsilateral peribronchial and/or hilar lymph nodes 
N1a : Metastasis to a single N1 nodal station 
N1b : Metastasis to two or more N1 nodal stations 
N2 :  Metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes 
N2a1 : Metastasis to one N2 nodal station with no involvement of N1 nodes 
N2a2 : Metastasis to one N2 nodal station and at least one N1 nodal station 
N2b : Metastasis to two or more N2 nodal stations 
N3 : Any of : Metastasis to scalene or supraclavicular lymph nodes or Metastasis to 
contralateral hilar or mediastinal lymph nodes 
 
   MX : Distant metastasis cannot be assessed 
M0 : No distant metastasis 
M1a : Any of : Separate tumor nodule in the other lung, Tumor with pleural or 
pericardial nodules or Malignant pleural or pericardial effusion 
M1b: A single metastasis outside the chest 
M1c: Two or more metastases outside the chest 
 
 
Tab. 1.5: Stage I-IV of lung cancer  
 
Treatment for lung cancer depends on the cancer's specific cell type, how far it has 
spread, and the person's performance status. Common treatments include palliative 
care, surgery, chemotherapy, and radiation therapy.  
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   The lung cancer five-year survival rate is 18.6% and the five-year survival rate for 
lung cancer is 56% for cases detected when the disease is still localized (within the 
lungs). Only 16% of lung cancer cases are diagnosed at an early stage. For distant 
tumors (spread to other organs) the five-year survival rate is only 5%. More than half 
of people with lung cancer die within one year of being diagnosed. 
 
1.5.3. Colorectal cancer 
 
 
Colorectal cancer (CRC) is the development of cancer from the colon or rectum 
(parts of the large intestine). A cancer is the abnormal growth of cells that have the 
ability to invade or spread to other parts of the body. 
 
   More than 75–95% of colorectal cancer occurs in people with little or no genetic 
risk. Risk factors include advanced age, male sex, high intake of fat, sugar, alcohol, 
red meat, processed meats, obesity, smoking, and a lack of physical exercise6162. 
 
   Colorectal cancer diagnosis is performed by sampling of areas of the colon 
suspicious for possible tumor development, typically during colonoscopy or 
sigmoidoscopy, depending on the location of the lesion61. It is confirmed by 
microscopical examination of a tissue sample. 
 
   Stage is typically made according to the TNM staging system from the WHO 
organization. 
 
 
TX : The primary tumor cannot be evaluated. 
T0 : No evidence of cancer in the colon or rectum. 
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Tis : carcinoma in situ (also called cancer in situ). Cancer cells are found only in the 
epithelium or lamina propria, which are the top layers lining the inside of the colon or 
rectum. 
T1 : The tumor has grown into the submucosa, which is the layer of tissue 
underneath the mucosa or lining of the colon. 
T2 : The tumor has grown into the muscularis propria, a deeper, thick layer of muscle 
that contracts to force along the contents of the intestines. 
T3 : The tumor has grown through the muscularis propria and into the subserosa, 
which is a thin layer of connective tissue beneath the outer layer of some parts of the 
large intestine, or it has grown into tissues surrounding the colon or rectum. 
T4a : The tumor has grown into the surface of the visceral peritoneum, which means 
it has grown through all layers of the colon. 
T4b : The tumor has grown into or has attached to other organs or structures. 
 
 
NX : The regional lymph nodes cannot be evaluated. 
N0 : No spread to regional lymph nodes. 
N1a : There are tumor cells found in 1 regional lymph node. 
N1b : There are tumor cells found in 2 or 3 regional lymph nodes. 
N1c : There are nodules made up of tumor cells found in the structures near the 
colon that do not appear to be lymph nodes. 
N2a : There are tumor cells found in 4 to 6 regional lymph nodes. 
N2b : There are tumor cells found in 7 or more regional lymph nodes. 
 
 
M0 : The disease has not spread to a distant part of the body. 
M1a : The cancer has spread to 1 other part of the body beyond the colon or rectum. 
M1b : The cancer has spread to more than 1 part of the body other than the colon 
or rectum. 
M1c : The cancer has spread to the peritoneal surface. 
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Stage I-IV of colorectal cancer is complicated. ( Tab. 1.6) 
 
 
 Tab. 1.6: Stage I-IV of colorectal cancer  
 
In general, the treatment of colorectal cancer is cure or palliation. However, the 
decision on which aim to adopt depends on factors, including the health situation of 
patient, preferences and the stage of the tumor. When colorectal cancer is early stage, 
surgery can be curative. However, when it is detected at later stages (metastases are 
present), the treatment is usually directed at palliation, to relieve symptoms caused by 
the tumor and keep the person as comfortable as possible6163. 
 
   According stage TNM, without N or M(N0 and M0): The colon cancer five-year 
survival rate is 90% and the five-year survival rate for rectal cancer is 89%; without M 
or written M0: The colon cancer five-year survival rate is 71% and the five-year survival 
rate for rectal cancer is 70%; once the situation of tumor reach to late stage (M1), the 
five-year survival rate reduce to 14%(colon cancer) and 15%(rectal cancer)64. 
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1.5.4. Kidney cancer 
 
   The kidney cancer, or named renal cancer is the abnormal cell of kidney growth 
without limited, and affect renal function. Commonly, the causes of kidney cancer 
include smoking, obesity, faulty genes, family history with kidney cancer, with kidney 
disease and need dialysis, being infected with hepatitis C and previous treatment for 
testicular cancer or cervical cancer. Obviously, there are other cause, like kidney stone 
and artery hypertension et. al. that are researching. 
 
According the pathophysiology and the tumor location, kidney cancer can be divide 
a several type. The most commonly types are renal cell carcinoma (RCC) and 
transitional cell carcinoma (TCC, also named urothelial carcinoma). Normally, blood 
and urine tests, biopsy and imagen tests (CT, X-Ray, MRI, IVP and Cystoscopy and 
nephro-ureteroscopy) are the way to diagnosis kidney cancer. In additional, the 
different type of kidney cancer develop with different way, that means there are 
different long-term outcomes. So, needs to make different treatment depend the stage 
and the type65. 
 
Stage TNM 
 
TX : The primary tumor cannot be evaluated. 
T0 : No evidence of a primary tumor. 
T1 : The tumor is found only in the kidney and ≤ 7 cm at its largest area. There has 
been much discussion among doctors about whether this classification should only 
include a tumor that ≤ 5 cm. 
T1a : The tumor is found only in the kidney and ≤ 4 cm at its largest area. 
T1b : The tumor is found only in the kidney and 4-7 cm at its largest area. 
T2 : The tumor is found only in the kidney and > 7 cm at its largest area. 
T2a : The tumor is only in the kidney and is > 7 cm but ≤ 10 cm at its largest area. 
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T2b : The tumor is only in the kidney and is > 10 cm at its largest area. 
T3 : The tumor has grown into major veins within the kidney or perinephric tissue, 
which is the connective, fatty tissue around the kidneys. However, it has not grown into 
the adrenal gland on the same side of the body as the tumor. The adrenal glands are 
located on top of each kidney and produce hormones and adrenaline to help control 
heart rate, blood pressure, and other bodily functions. In addition, the tumor has not 
spread beyond Gerota's fascia, an envelope of tissue that surrounds the kidney. 
T3a : The tumor has spread to the large vein leading out of the kidney, called the 
renal vein, or the branches of the renal vein; the fat surrounding and/or inside the 
kidney; or the pelvis and calyces of the kidney, which collect urine before sending it to 
the bladder. The tumor has not grown beyond Gerota's fascia. 
T3b : The tumor has grown into the large vein that drains into the heart, called the 
inferior vena cava, below the diaphragm. The diaphragm is the muscle under the lungs 
that helps breathing. 
T3c : The tumor has spread to the vena cava above the diaphragm and into the right 
atrium of the heart or to the walls of the vena cava. 
T4 : The tumor has spread to areas beyond Gerota's fascia and extends into the 
adrenal gland on the same side of the body as the tumor. 
 
NX : The regional lymph nodes cannot be evaluated. 
N0 : The cancer has not spread to the regional lymph nodes. 
N1 : The cancer has spread to regional lymph nodes. 
 
M0 : The disease has not metastasized. 
M1 : The cancer has spread to other parts of the body beyond the kidney area. 
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Tab.1.7: Stage I-IV of kidney cancer  
 
Surgery is the most common treatment as kidney cancer does not often respond to 
chemotherapy and radiotherapy. It usually be removed by surgery, if the cancer without 
metastasis. In some special cases, may remove the whole kidney. However most 
tumors are amenable to partial removal to eradicate the tumor and preserve the 
remaining normal portion of the kidney. If the cancer cannot be treated with surgery, 
other techniques such as freezing the tumor or treating it with high temperatures may 
be used. Certainly there are some new treatment opinion with the technique developed, 
like biological therapies and immunotherapy66. Although the new technique developed 
fast, but the survival rate of end-stage also lower (Tab.1.8). 
 
 
   Tab.1.8: Survival rate of kidney cancer  
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1.5.5. Prostate cancer 
 
The prostate is a little-sized gland with peculiar of male, and the main function is 
making seminal fluid. With the men get older, prostate increase it’s size and lead 
benign prostatic hypertrophy(BPH). BPH is a common in old male people and the 
symptoms likes the cancer. In fact, BPH is not related with prostate cancer. 
 
The prostate cancer is not clear symptoms in early stage. However, there are 
several symptoms that are similar with BHP caused by prostate cancer, such as, 
frequent urination, nocturia, difficulty starting and maintaining a steady stream of urine, 
hematuria, and dysuria67. 
 
   As known, obesity, age and family history are the major risk factors caused prostate 
cancer. The morbidity of prostate cancer is variational rate that is increasing with the 
age get older. It’s uncommon to see a patient who has been diagnosis prostate cancer 
under 45 years old. The age of diagnosis is approximately 75 years old. The main 
method of diagnosis are digital rectal examination (DRE), cystoscopy, transrectal 
ultrasonography and tumor marker (PSA), but the most important method to diagnosis 
and confirmation the cancer is biopsy68. 
 
Obviously, for make the treatment regimen, know stage of cancer is necessary. 
Due to the DRE and PSA can make sure that the cancer is activity, there are several 
different stage to describe prostate cancer such as Stage TNM, Gleason score and 
Stage groping69(Tab. 1.9). 
 
Stage TNM 
 
Clinical T 
TX: The primary tumor cannot be evaluated. 
T0: There is no evidence of a tumor in the prostate. 
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T1: The tumor cannot be felt during a DRE and is not seen during imaging tests. It 
may be found when surgery is done for another reason, usually for BPH or an abnormal 
growth of noncancerous prostate cells. 
T1a: The tumor is in 5% or less of the prostate tissue removed during surgery. 
T1b: The tumor is in more than 5% of the prostate tissue removed during surgery. 
T1c: The tumor is found during a needle biopsy, usually because the patient has an 
elevated PSA level. 
T2: The tumor is found only in the prostate, not other parts of the body. It is large 
enough to be felt during a DRE. 
T2a: The tumor involves one-half of 1 side of the prostate. 
T2b: The tumor involves more than one-half of 1 side of the prostate but not both 
sides. 
T2c: The tumor has grown into both sides of the prostate. 
T3: The tumor has grown through the prostate on 1 side and into the tissue just 
outside the prostate. 
T3a: The tumor has grown through the prostate either on 1 or both sides of the 
prostate. This called extraprostatic extension (EPE). 
T3b: The tumor has grown into the seminal vesicle(s), the tube(s) that carry semen. 
T4: The tumor is fixed, or it is growing into nearby structures other than the seminal 
vesicles, such as the external sphincter, the part of the muscle layer that helps to 
control urination; the rectum; the bladder; levator muscles; or the pelvic wall. 
 
Pathological T (there is not TX, T0 and T1 in pathological T) 
T2: The tumor is found only in the prostate. 
T3: There is EPE. The tumor has grown through the prostate on 1 or both sides of 
the prostate. 
T3a: There is EPE or the tumor has invaded the neck of the bladder. 
T3b: The tumor has grown into the seminal vesicle(s). 
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T4: The tumor is fixed, or it is growing into nearby structures other than the seminal 
vesicles, such as the external sphincter, the part of the muscle layer that helps to 
control urination; the rectum; the bladder; levator muscles; or the pelvic wall. 
 
The stage N and M no present clinical or pathological. 
 
NX: The regional lymph nodes cannot be evaluated. 
N0: The cancer has not spread to the regional lymph nodes. 
N1: The cancer has spread to the regional (pelvic) lymph node(s). 
 
MX: Distant metastasis cannot be evaluated. 
M0: The disease has not metastasized. 
M1: There is distant metastasis. 
M1a: The cancer has spread to nonregional, or distant, lymph node(s). 
M1b: The cancer has spread to the bones. 
M1c: The cancer has spread to another part of the body, with or without spread to 
the bone. 
 
 
 
Gleason score 
 
Gleason X: The Gleason score cannot be determined. 
Gleason 6 or lower: The cells are well differentiated, meaning they look similar to 
healthy cells. 
Gleason 7: The cells are moderately differentiated, meaning they look somewhat 
similar to healthy cells. 
Gleason 8, 9, or 10: The cells are poorly differentiated or undifferentiated, meaning 
they look very different from healthy cells. 
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Gleason scores are often grouped into simplified Grade Groups: 
Grade Group 1 = Gleason 6 
Grade Group 2 = Gleason 3 + 4 = 7 
Grade Group 3 = Gleason 4 + 3 = 7 
Gleason Group 4 = Gleason 8 
Gleason Group 5 = Gleason 9 or 10 
 
 
           Tab. 1.9: Stage groping(I-IV) of prostate cancer  
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1.6. Immunosuppression in liver transplantation 
 
 
The objective to make patient with liver transplantation intaking 
immunosuppressive drug is controlling and withstanding the acute rejection or chronic 
rejection. The rejection is a normal result because it is about genetic incompatibility 
between donor and recipient. Due to the donor’s liver is an  exotic organ for recipient, 
the immune system of recipient reacts to against the donor’s histocompatibility 
antigens. Because recipient intake the immunosuppressive drug that reduces ability of 
immune, the risk of infection and development of tumors relative increase. So, one 
successful transplantation is not just finisher an operation, is find a balance between 
the rejection with graft can not work and the risk of infection increasing. 
 
With the development of technique and pharmacology, there are kinds of drug can 
be selected. At same time, the immunobiology knowledge can show us the 
mechanisms of action of the drugs and the key point of the immune reaction70. 
 
The experience in the last 20 years makes us to know the immunosuppressive drug 
and the regimen must be adapted to each recipient. Depend the different factors(age, 
gender, race, indication of transplant, relative disease and general situation) of 
recipient to make the immunosuppression regimen individual. The aim of 
immunosuppressive therapy are not just for maintain the graft, and increase the quality 
of recipient’s life 
 
Certainly, the toxic effects of the different immunosuppressive drug such as Artery 
hypertension, Kidney failure, Diabetes mellitus, brain alterations et.al.) are allowed 
before the LT. If can reach a situation that the immunosuppressive drug has been 
withdrawn without reaction of rejection, that would be a liver transplantation 
successfully. 
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1.6.1. Calcineurin inhibitors 
 
   The calcineurin inhibitors bind to calcineurin, inhibiting calciumdependent activation 
of the synthesis and release of IL-2, and the result is the inhibition of IL-2 gene 
transcription and T cell activation and proliferation71. 
 
   Now, CNIs are the basis of immunosuppressive treatment protocols after OLT, and 
cyclosporine-A (CyA) and tacrolimus are the two CNIs approved for use in organ 
transplantation. So, several studies have been compared the safety and efficacy 
between CyA and Tacrolimus to decide the drug of choice. In some studies, it seems 
tacrolimus is more powerful than CyA, especially in term to prevent acute rejection and 
improve the survival of recipient and graft. However, another more recent multi-center 
trial showed no significant differences between the two medications with regard to 
acute rejection episodes, death or graft loss71.  
As we known, CNIs have a wide range of toxicities such as, Nephrotoxicity and 
Neurotoxicity. Tacrolimus has a higher incidence of diabetes and tremor than CsA, on 
the other hand, CyA present the higher incidence of artery hypertension and gingival 
hyperplasia. For these reasons, we do not have objective data to decide which of them 
should be the better choice of CNI agents for all patients7172. 
 
 
1.6.1.1. Tacrolimus 
 
Tacrolimus also named FK506, it is a 23-membered macrolide lactone that was 
first discovered in 1987 from the bacterium Streptomyces tsukubaensis. With a 
liposoluble nature and the mechanism of action similar to CyA, despite its different 
chemical structure and with a power of 100 times higher73. Compared the efficacy with 
CyA, the most research present there are not conspicuous different. In any case, 
although the long-term results do not show differences between CyA and tacrolimus, 
however, in the short-term it seems that the tacrolimus presents lower incidence of 
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acute rejection and cardiovascular risk, many units of transplants indicate to use 
tacrolimus71. The mechanism action of tacrolimus is similar with CyA, activating after 
binding to its intracellular receptor, an immunophilin called FK506 binding protein-12 
(FKBP12). Like CyA, the FKBP-FK506 complex has no effect on the calcium-
independent activation of T cells. The different point is that tacrolimus has the 
additional property of interfering with the expression of IL-4 receptors of B lymphocytes, 
of inhibiting the synthesis of IL-5 (B cell differentiation factor) to reducing expression 
of adhesion molecules in endothelial cells and block the response of leukocytes to IL-
87475. 
 
Oral tacrolimus is slowly absorbed in the tract of duodenum and jejunum without 
depending on bile production. After intake 1.5-3 hours, the highest maximum 
concentrations (Cmax) reached. The total bioavailability is very low, just 20 to 25%. In 
the blood, tacrolimus is mainly bound to erythrocytes, especially albumin; more than 
98.8% are bound to plasma proteins. The substance is metabolized in the liver, for this 
reason, liver failure produces an increase in their plasma levels. Biological half-life 
varies widely, due to differences in clearance. Tacrolimus is predominantly eliminated 
via the faeces in form of its metabolites. Less than 1% is actively eliminated by the 
kidneys or fecal route, so it does not need to modify its dose in case of renal failure 
(unless renal failure is attributed to the drug)73. 
 
1.6.1.2. Toxicity of calcineurin inhibitors 
 
CNIs present multiple and relatively adverse side effects. The most frequent and 
related are nephrotoxicity, neurotoxicity and de de novo neoplasia. 
 
l Nephrotoxicity 
 
   As described above, nephropathy is an important complication of post-LT, and the 
it is caused by used of CNI. The mechanism and action of CyA and tacrolimus are 
 63 
similar, although with different structure. The incidence of nephrotoxicity due to CNI, 
although using low doses, is 20% present chronic renal failure within 5 years71. 
 
   The CNIs cause to two different nephrotoxicity at high levels. The first is called 
acute nephrotoxicity associated with acute renal failure reversible and is characterized 
by a decrease in glomerular filtration and renal plasma flow that produce an increase 
in creatinine and urea. And induce renal dysfunction and also tubular injury caused 
CNIs afferent renal arteriolar vasoconstriction. This vasoconstrictor effect is dose 
related and reversible70. 
 
On the other hand, the chronic renal nephrotoxicity that occurs long-term after 6-
12 months of the beginning of treatment and advanced renal failure in 8% to 28%76. 
The characterized by the development of chronic renal failure whose pathophysiology 
is characterized by the presence of structural lesions, such as fibrosis. interstitial and 
the appearance of renal vascular sclerosis, not being reversible despite decreasing 
the dose and in some cases progressing to end-stage renal failure and dialysis.  
 
l De novo neoplasia  
 
With the immunosuppressive agent used, the immune of humans reducing by time, 
so the de novo neoplasm is also a complication post-LT and associated relationally 
with CNI. The incidence of post-transplant cancer has a clear relationship with the time 
of exposure to immunosuppressive treatment. Cancer is currently one of the major 
limitations of the expectation and quality of life of the patient carrying a solid organ 
transplant. Experimental and clinical arguments support an association between the 
immunosuppressed state and cancer. CNI increases the expression of transforming-
growth factor beta(TGF-β), which favors the appearance of several factors of an 
invasive phenotype of neoplastic cells, of the angiogenesis induce vascular endothelial 
growth factor and of interleukin-6, which increases Epstein-Barr virus-induced B-cell 
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growth.18 Moreover, cyclosporine interferes with DNA repair among in vitro cultured 
white blood cells from renal transplant recipients76. 
 
 
1.6.2. Mycophenolate-mofetil 
 
Mycophenolate-mofetil (MMF) is an immunosuppressive agent used to prevent 
rejection in organ transplantation. Discovered by Italian medical scientist Bartolomeo 
Gosio in 1893, mycophenolic acid was the first antibiotic to be synthesised in pure and 
crystalline form. MMF was approved by the FDA in 1995. 
 
Mechanism of action 
 
MMF was the observations that suggested that the de novo pathway of purine 
synthesis, and not the recovery pathway, was crucial for the proliferative response of 
human T and B lymphocytes. 
 
Mycophenolate mofetil (MMF) undergo immediate first-pass metabolism in the liver 
into the active compound mycophenolic acid (MPA). MPA inhibits inosine-5'-
monophosphate dehydrogenase (IMPDH). IMPDH inhibition particularly affects 
lymphocytes since they rely almost exclusively on de novo purine synthesis. 
 
Clinical use 
 
In general, it has been used mainly associated with anti-calcineurin or as a drug to 
be added in case of toxicity to CyA or tacrolimus given the need to reduce the dose of 
these due to the side effects they cause73. 
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It has also been observed that the use of MMF has a beneficial effect in the 
prevention of chronic graft nephropathy, which is in part independent of the reduction 
of the acute or chronic rejection rate. 
 
 
Adverse effects 
 
Because of the mechanism of action, it alters other types of dividing cells, so 
fundamentally its side effects include gastrointestinal disorders, spinal toxicity and to 
a lesser extent opportunistic infections and respiratory tract disorders. 
 
First, the digestive disorders include diarrhea, nausea, vomiting and joint pain. 
These usually involve the suppression of treatment in only 5% of cases. 
 
Opportunistic infections: All transplant patients are at the situation that increasing 
risk of opportunistic infections, the most common in patients treated with MMF (2 or 3 
g / day, but patients may tolerate the drug better if started at 500mg twice a day or four 
times a day73.) in OLT are fungal (mainly Candida) and viral (viremia / CMV disease 
and Herpes simplex). 
 
Unlike other immunosuppressive agents used in the OLT, no clinically significant 
adverse effects have been found as a direct consequence of the use of MMF such as 
nephrotoxicity, hepatotoxicity. 
 
 
1.6.3. mTORi 
 
Sirolimus, or called rapamycin, is a macrolide compound, and it is produced by the 
bacterium Streptomyces hygroscopicus and was isolated for the first time in 1972 by 
Surendra Nath Sehgal and colleagues from samples of Streptomyces hygroscopicus 
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found on Easter Island77, where it received its initial name. Sirolimus was initially 
developed as an antifungal agent in 1975, later demonstrating its immunosuppressive 
activity in vitro. However, this use was abandoned when it was discovered to have 
potent immunosuppressive and antiproliferative properties due to its ability to inhibit 
mTOR. 
 
In recent years, there is other inhibitor was developed with the similar mechanism 
of sirolimus, called Everolimus that is the 40-O-(2-hydroxyethyl) derivative of sirolimus 
and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin 
(mTOR). 
 
Mechanism action of mTORi 
 
This therapeutic group has also been called Proliferation Signal Inhibitors (ISP) and 
has some advantages over classical immunosuppressants that have aroused great 
interest. It acts through blocking signal 3 of cell activation from IL-2 receptors in T-cells 
and B-cells. Interestingly, despite binding to the same cell receptor, sirolimus and 
tacrolimus do not compete with each other and act synergistically70. The mTOR protein 
forms two structurally and functionally distinct complexes, mTORC1 and mTORC2, 
both of which play different roles downstream. mTORC1 is activated by growth factors, 
amino acids and controls of cell proliferation, promoting processes such as DNA 
translation, RNA transcription, ribosomal biogenesis, and cell cycle progression7778. 
 
Because the antiproliferative effects, it is useful in the artery of chronic rejection. In 
addition to blocking the cell cycle progression induced by IL-2, it facilitates apoptosis, 
acting synergistically with the blocking of the costimulatory signal in the reduction of 
alloreactive lymphocytes, which also differentiates it from anti-calcineurins, which 
block apoptosis. This is relevant because apoptosis has been related to the 
development of allograft tolerance mechanisms. 
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1.6.3.1. Pharmacokinetics of Sirolimus 
 
Absorption 
 
Sirolimus is absorbed quickly that means whole-blood sirolimus concentrations 
(Cmax) occur 1 hour after administration of single doses and 2 hours after multiple doses 
in stable renal transplant patients, The bioavailability of sirolimus is 14%. Co-
administration with fatty foods delays the rate of absorption, in this way the Cmax 
decreases by 34%, the tmax increases 3.5 times, and the area under the curve of 
plasma concentrations vs. Time (AUC) is also increased by 35% when compared to 
the values obtained in fasting79. 
 
Metabolism 
 
Sirolimus undergoes extensive oxidative metabolism at the liver level, after incubation 
with human liver ,icrosomes to yield multiple demethylation and hydroxylation 
reactions. It originates a large number of metabolites, and in appearance these partially 
preserve the activity of the original molecule79. 
 
Excretion 
 
According to the result of the health volunteers intake labeled sirolimus with single oral 
dose, The excretion is mostly fecal (91.1%), with urinary elimination being low (2.2%). 
After the administration of multiple doses to kidney transplant patients, the elimination 
half-life (t1 / 2) was 62 hours and mean oral-dose clearance (Cl / F) 210 ml / h / kg79. 
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1.6.3.2. Pharmacokinetics of Everolimus 
 
Absorption 
 
The oral bioavailability of everolimus is 16%, little higher than sirolimus. Everolimus 
reaches the maximum concentration after 1 or 2 hours after intake with oral 
administration. Based on the ratio of areas under the concentration / time curve (AUC 
ratio), the relative bioavailability of the dispersible tablet versus the conventional tablet 
is 0.90 (90% CI 0.76 - 1.07)80. 
 
Distribution 
 
The blood / plasma rate of everolimus depends on the concentration. The binding 
to plasma proteins is approximately 74% in healthy individuals and in patients with 
moderate hepatic insufficiency. 
 
Metabolism 
 
Everolimus is one of the substrates of CYP3A4 and P-glycoprotein. The main 
metabolic pathways identified in humans are monohydroxylations and 0-dealkylations. 
Two major metabolites are formed by hydrolysis of the cyclic lactone. Everolimus is 
the predominant form in blood circulation. None of the major metabolites contribute 
significantly to the immunosuppressive activity of everolimus81. 
 
Excretion 
 
Same to the experimentation of Sirolimus. After the administration of a single dose 
of radioactive everolimus to patients treated with ciclosporin after transplantation, most 
of the radioactivity (80%) was found in the faeces and only a small proportion (5%) in 
the urine82. And researcher undetected the original compound in urine and faeces. 
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1.6.3.3. Adverse effects 
 
The main side effect is hyperlipidemia, present in approximately 44% of patients, a 
higher percentage than other immunosuppressive drugs. The presence of 
thrombopenia and leukopenia is also very frequent, although both are reversible in 90% 
of cases83. 
 
Some studies have shown a higher survival of the graft while others have described 
a relative myelosuppression. mTORi is regulated in eukaryotic cells by the PI3K / Akt 
metabolic pathway. Those cells with a mutation in the PTEN and PI3K genes present 
a release of the control of this pathway, so that the inhibition of mTOR would act 
effectively in the neoplastic control. It should be noted that there is an initial work that 
describes an increased risk of arterial thrombosis in patients who received sirolimus, 
although this finding has not been reproduced in other studies82. 
 
Use of these drugs in liver transplantation for malignancies (hepatocellular 
carcinoma, cholangiocarcinoma, neuroendocrine tumors metastatic), malignant 
tumors de novo (cutaneous carcinomas, gastric cancer, breast cancer, etc), renal 
failure associated with CNI, previous renal failure that does not improve after 
transplantation and immunosuppression in patients with acute or chronic cortico-
resistant rejection84. 
 
The potential risks of mTOR inhibitors, including hypercholesterolemia, thrombosis 
and problems in wound healing, have also been highlighted in this population segment. 
No controlled study has examined these critical endpoints in the OLT setting. 
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1.6.3.4. mTORi in the field of oncology  
 
The incidence of de novo neoplasia that occur after OLT is higher than that of 
malignant tumors developed in the general population, because of the recipient must 
administration immunosuppressive agent for lifelong85. 
 
Immunosuppressive therapy decreases the immune response against malignant 
cells and against a large variety of viruses with oncogenic properties. Likewise, it has 
been described in a recently published randomized trial that cirrhotic patients of enolic 
origin had a much higher risk of non-hepatic neoplasia in the case of having been 
transplanted, in contrast to those who did not receive a transplant and followed a 
treatment standard for their pathology (at 5 years, the risk of neoplasia was 37% versus 
6%). This increased risk is especially high in neoplasms related to viral infections, such 
as non-Hodgkin's lymphoma, Kaposi's sarcoma and cervical cancer. The risk of skin 
cancer is also greatly increased in these patients8687. 
 
The incidence of other common cancers seems to be increased too, but this risk is 
not high. Some studies shown that the incidence of colorectal, lung, head and neck, 
urological, and hepatocellular carcinomas increases after receiving lifelong 
immunosuppressive therapy888990. In some cases, the cause of this increased risk may 
be a specific association between certain causes of liver disease and risk factors for 
the development of certain types of neoplasia in the general population: there is an 
association between primary sclerosing cholangitis and ulcerative colitis, which 
markedly increases the risk of colorectal cancer. 
 
In patients with alcoholic liver disease, the risk of esophageal cancer and cancer of 
the head and neck is increased of tumors diagnosed most frequently in patients post-
transplant. And it may have the association with high alcohol intaking and smoking, 
which is a very important risk factor for some patients. 
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mTOR, a protein of the group of kinases, is involved in cellular metabolic regulation 
PI3K / Akt. Its activation, in response to growth, nutrient and energy signals, leads to 
an increase in the synthesis of proteins necessary for the development and growth of 
tumors. This feature makes mTOR an important target for cancer therapy77. 
 
The first generation of mTORi, sirolimus and its derivatives, everolimus have been 
widely evaluated in patients with cancer. On the other hand, the second generation 
mTORi, small molecules with action in the field of kinases, are also in full clinical 
development. Clinical trials are under way to identify additional malignancies that 
respond to mTORi, either in single or combined therapy. Future research should 
evaluate the most appropriate terpeutic regimes as well as target populations. 
 
Same to all immunosuppressive agents, the sirolimus also decreases the 
antioncogenic activity of the organism and allows the proliferation of some cancers 
which would normally be destroyed. Immunosuppressed patients have a cancer risk 
10 to 100 times higher than the general population. In addition, patients who currently 
have or have been treated for cancer, develop a higher rate of tumor progression as 
well as recurrence in relation to patients with an intact immune system909192. 
 
1.6.3.4.1. Hepatocellular carcinoma recurrence 
 
HCC is the most common in primary liver cancer with(70-85%), and it had been the 
third most frequent cause of death-related-cancer in the world93. As we know, liver 
transplantation is the ultimate treatment of end-stage HCC. Due to against reaction 
rejection of organ, from AZA to CNIs, and to mTORi, many regimens were be chosen 
for reduce the complications post-LT to lower. As mentioned above, mTORi has been 
used as anticancer drug. 
 
The exact mechanism for this increased risk is unknown, although preclinical data 
suggest that CNIs may actually promote tumor growth. In contrast, other data suggest 
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that immunosuppression regimens that include rapamycin (sirolimus) or its analogs 
reduce the risk of HCC recurrence as well as the development of de novo malignancies 
after orthotopic liver transplantation, while successfully avoiding allograft rejection and 
improving overall survival93. 
 
The rate of HCC recurrence post-LT is between 13-27%. A meta-analysis indicated 
the risk factors on pre-transplant risk for HCC recurrence showed significant 
correlations for the presence of vascular invasion, level of differentiation, tumor size, 
and tumor stage outside the Milan criteria. As vascular invasion and a tumor size >5 
cm are included in a tumor stage considered exceeding the Milan criteria, the only risk 
factor identified within this meta-analysis for patients with a tumor stage within the 
Milan criteria was a moderate or poorly differentiated HCC94. 
 
Theoretically, HCC recurrence can use all modalities for treating HCC. However, 
HCC recurrence after LT is considered a “systemic disease”, and the efficacy of 
locoregional treatment for a systemic disease is doubtful. Because for the recipient, 
use immunosuppressive agent can affect wound healing and increace the rate of 
infection. And the operation of liver transplantation may damage or change the 
structures of vascular in anatomy. Due to these reasons, it may be difficult in 
interventional radiological procedures like TACE. So, some studies present a new 
treatment for intrahepatic recurrent, High-intensity focused ultrasound (HIFU) ablation. 
And on the other hand, change the inhibitor non-mTORi to mTORi is a regimen can be 
used95. 
 
1.6.3.4.2. De novo neoplasia 
 
Due to the more prolonged exposure to immunosuppression is associated with an 
increased frequency of developing neoplasms, the rate of De novo neoplasia almost 
reached 30% at 10 years in patient after liver transplantation and it is the most common 
cause to death in 1-year of recipient after liver transplantation. Compare with general 
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population, same level of the age and gender, there are 2-4 times higher of risk to 
occur malignancy96. 
 
De novo malignancy after liver transplantation has become a major source of 
morbidity and mortality97. As mentioned above, used inhibitor is the most important 
factor that can increase risk to occur malignancy. Obviously, there are the association 
factors with cancer risk such as: age, gender, race, alcohol intake, smoking and history 
of cancer et.al.91  
 
Age: Advanced age as a risk factor for almost all disease, as the well described 
risk factor for de novo neoplasia after LT. This suggests that other factors may 
supersede age in cancer risk, though some caveats are notable with the extremes of 
age. A study reported, LT recipients older than 60 years had > 2 times higher 5-year 
incidence of new cancers (> 40%) compared to younger LT recipients (< 20%), with 
significantly higher cancer related mortality91. 
 
Gender and race: There is conflicting data on the relative risk of de novo 
malignancy according to gender, with slightly higher sirolimus of cancers in females in 
one registry study, and in males in another, limiting any meaningful conclusion. A study 
indicate that Non-Caucasian race was associated with a significantly increased risk of 
de novo malignancy, but the small size of that subgroup was limiting9192. 
 
Indication for LT: Patients who receive LT and conform to one of indications are 
more prone to occur malignancies. There are some research of multicenter in USA 
discovered that the patient with primary sclerosing cholangitis exhibited an increased 
risk for lymphoproliferative disorder (PTLD), skin malignancies and solid organ 
malignancies. And the highest cumulative incidence of non-skin cancer of 5.5%, 10.4%, 
and 21.9% at 1, 5, and 10 years, respectively. 
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Alcohol intake and smoke: Smoking is a significant predictor of de novo 
malignancies on analysis, and many studies have described the carcinogenic 
properties of alcohol and smoking in immunocompetent individuals. Alcoholic liver 
disease is associated with increased cancer risk post-LT. The synergy between the 
alcohol intake and smoking to affect carcinoma has been described919298. 
 
History of cancer: A history of cancer prior to LT was not associated with its 
recurrence after LT. However, LT for HCC has been associated with an increased risk 
of de novo malignancy, and we have mentioned above. 
 
 
The risk of de novo malignancy is variable across a range of tumor types, and 
normally grouped three categories that including: skin cancers, lymphoproliferative 
disorder (PTLD) and solid organ cancers. 
 
l Skin cancer 
 
Skin cancer is the most common malignancy occurring in the situation after OLT 
and immunosuppression, except these, male sex, age older than 55 years and 
ultraviolet radiation also are the important risk factor in the pathogenesis of skin 
malignancies, and exerts a field cancerization mutagenic effect in exposed areas of 
the skin91. The incidence of skin cancer increases with extended survival after OLT. 
These cancer include squamous cell cancer (SCC), basal cell cancer (BCC) and 
melanomas, and the rate of SCC, BCC and melanomas are 50%, 40.9% and 9.1%, 
respectively919699. Malignant melanoma is the most serious form of skin cancer, and 
Early identification and surgical removal is currently the only proven therapy for 
melanoma99. 
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Compare with general population, SCC is more common than BCC in recipient of 
transplantation. Additionally, while SCC and BCC are easily surveyed and resected, 
SCC can behave more aggressively in LT recipients91. 
 
l Lymphoproliferative disorder (PTLD) 
 
Lymphoproliferative disorder (PTLD) is the second commonly malignancy in patient 
post-LT, and its widely distribution of age that even to the very young patient. PTLD 
encompasses a heterogeneous group of diseases characterized by excessive 
proliferation of lymphoid cells and it commonly caused by de novo infection, or 
reactivation of latent Epstein-Barr virus (EBV)96. Compared to other solid organ 
transplantation recipient, the rate of PTLD is lower in LT, that may due to lower 
immunosuppression levels needed to prevent liver allograft rejection, and possibly a 
smaller number of donor lymphocytes in the graft91. 
 
Some studies reported that the incidence frequency in pediatric patient is higher 
than adult, almost 3 fold. This is likely a reflection of the EBV negative status of 
pediatric recipient, whereas EBV infects 90% of the adults worldwide. The 
immunosuppressive regimen is very important for the recipient post-LT with PTLD, 
especially the use of anti-lymphocytic serum and tacrolimus in children. The indication 
for transplantation is also important, as the risk of PTLD in patients transplanted for 
sclerosing cholangitis is more than 20%; alcoholic cirrhosis and viral hepatitis are 
indications associated with an increased incidence of PTLD in adult recipients100. 
 
The diagnosis is based on tumor biopsy with molecular characterization of clonality. 
It is important to test the tumor for EBV, as the results have diagnostic, prognostic and 
therapeutic implications. 
 
There are some therapy for PTLD such as, Withdrawal of immunosuppression, and 
surgery; Antiviral treatment; Chemotherapy and Immunotherapy (“Interferon-a and IL-
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6”, “Anti-B cell monoclonal antibodies” and “Adoptive immunotherapy with virus-
specific T cells”). 
 
PTLD used to be highly lethal and 40–60% of solid organ recipients dead caused 
it. The prognosis has improved markedly with the use of new therapeutic approaches 
such as monoclonal antibodies and T-cell therapy. The overall survival rate of patients 
with PTLD is conservative, especially the rate of children is higher than in adults, with 
65% of survival rate at 15 years in children compared to 39% for adults, and 55% at 
10 years in adult and pediatric recipients with PTLD100. 
 
l Kaposi’s sarcoma (KS) 
 
KS is a multifocal angioproliferative mucocutaneous neoplasm driven by HHV-8 
infection and represents approximately 4% of all post-transplant tumors. Compared 
with general population, the risk occurring neoplasia increasing 500 fold in patient who 
receive organ transplantation96. In some reported that the incidence of KS occurring 
recipient after LT is low, although the rate is higher than patient kidney transplantation 
(KT)101. 
 
Unlike others de novo neoplasia, the incidence of KS is reducing with the time after 
transplantation. Moreover, a study present the evidence to the usefulness of mTOR 
inhibitors in treating this tumor while at the same time providing effective 
immunosuppression96102. 
 
l Lung cancer 
 
Obviously, the incidence of lung cancer increasing compared with general 
population. Expect long-term used immunosuppressive agent after transplantation, the 
risk factor of occur cancer almost as well as mentioned above. Especially smoking, as 
same as general population, its the most important factor to occur lung cancer. 
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According to the epitemiological related, in general, smoker always are heavy drinker, 
so the patients with alcohol-related cirrhosis as an indication for LT had higher rates of 
lung cancer than those who underwent LT for other indications96. 
 
For novo lung cancer after transplantation, the stage TNM and stage grouping are 
not different with mentioned above. 
 
In principal, surgical is a good choice to solution. Pathological type of de novo lung 
cancer was adenocarcinoma and squamous cell carcinoma. Contraindications for 
surgery such as, cancer with malignant effusion; cancer with multiple pulmonary 
metastases or metastases distal; small cell lung cancer and others unresectable 
advanced cancer103. 
 
The survival rate of lung cancer de novo after LT is low, just 37.5% of 1-year. 
 
 
l Colorectal cancer 
 
The incidence of colorectal cancer (CRC) of patient post-LT increasing clearly 
compared with the general population. In general, some recipient preexisting risk 
factors for CRC such as primary sclerosing cholangitis (PSC) and associated 
inflammatory bowel disease (IBD), and these disease make an increasing risk of 
CRC103104105. 
 
The risk factors for increased incidence of de novo CRCs are considered to be age > 
45 years, diagnosis of PSC, an intact colon, colonic polyps, and a longer duration of 
ulcerative colitis. 
 
Due to the complication of post-transplantation, differential diagnoses in the post-
transplantation period would be broader and include post-transplantation 
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complications such as rejection, intestinal ischemia, biliary complications, bowel 
obstructions caused by adhesions, internal hernias, and volvulus. Therefore, they 
require careful and extensive workup. Except CRC, the neoplastic bowel obstructions 
in this population might also be secondary to post-transplantation lymphoproliferative 
disease. As we know, diarrhea is a adverse effect of inhibitor immunosuppressive, 
confirm the cause of diarrhea also need a systemic approach like endoscopy and 
biopsy. And the CT might have an important role in the evaluation of suspected 
colorectal neoplasia and its potential metastatic diseases105106. 
 
The main regimen to treat colorectal cancer de novo are colectomy and 
chemotherapy o radiation therapy. Its depend the situation of patient and the stage of 
cancer to decide. A notice worthful is that the agents for chemotherapy need to have 
reasonable activity in the post–liver transplantation setting. However, further 
delineations of specific dosing, drug interactions with immunosuppressive agents, and 
safety on graft tolerance should be carefully105. 
 
More frequently diagnosed between 16 and 50 months after transplant, colorectal 
cancer in transplant recipients tends to be detected at an earlier age and has been 
associated with a worse prognosis compared to the general population. However, no 
data to shown the survival rate of LT recipient after diagnosed novo colorectal cancer96. 
 
l Oropharyngeal cancer 
 
Neck neoplasms is more frequent in the LT recipient than in the general population, 
and mean time to diagnosis is reportedly between 34.3 months and 61.2 months96. 
 
Oropharyngeal cancer is 25.5 fold more frequent in patients transplanted for 
alcohol-related cirrhosis compared with transplanted for other indications, and the 
carcinogenic effects of smoking observed in the general population also applies for 
transplant recipients. In general, heavy smoker also tend to be heavy drinker. Due to 
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these reasons, smoke and alcohol are the important factor risk for oropharyngeal 
cancer96. 
 
Clinically, used the stage TNM and stage grouping (Tab. 1.10) to confirm regimen 
of treatment. 
 
T: 
TX: The primary tumor cannot be evaluated. 
Tis: Describes a stage called carcinoma (cancer) in situ. This is a very early cancer 
where cancer cells are found only in 1 layer of tissue. 
T1: The tumor is 2 centimeters (cm) or smaller at its greatest dimension. 
T2: The tumor is larger than 2 cm but not larger than 4 cm. 
T3: The tumor is larger than 4 cm or has spread to the epiglottis, which is the flap 
of cartilage that diverts food into the esophagus. 
T4a: The tumor has invaded the larynx, muscle of the tongue, muscles in the jaw, 
roof of the mouth, or jawbone. 
T4b: The tumor has invaded muscles and bones in the region of the mouth; the 
nasopharynx, which is the air passageway at the upper part of the throat behind the 
nose; or the base of the skull, or the tumor encases the carotid artery. 
 
N: 
NX: The regional lymph nodes cannot be evaluated. 
N0: There is no evidence of cancer in the regional lymph nodes. 
N1: The cancer has spread to a single lymph node on the same side as the primary 
tumor, and the cancer found in the node is 3 cm or smaller. There is no ENE. 
N2a: Cancer has spread to a single lymph node on the same side as  
the primary tumor and is larger than 3 cm but not larger than 6 cm. There is no ENE. 
N2b: Cancer has spread to more than 1 lymph node on the same side as the primary 
tumor, and none measures larger than 6 cm. There is no ENE. 
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N2c: Cancer has spread to more than 1 lymph node on either side of the body, and 
none measures larger than 6 cm. There is no ENE. 
N3a: The cancer is found in a lymph node and is larger than 6 cm. There is no ENE. 
N3b: There is ENE in any lymph node. 
 
M: 
M0: Cancer has not spread to other parts of the body. 
M1: Cancer has spread to other parts of the body. 
 
 
Tab. 1.10: Stage Group (I-IV)  
 
For the patient of LT, the diagnosis is same to general population. Usually used 
imagen test such as X-Ray, CT and MRI; endoscopy and biopsy also are the test 
diagnosis for oropharyngeal cancer107. Depend the stage, the regimen of therapy can 
be chosen surgical, radiation therapy o expectant therapy. 
 
The survival rate of oropharyngeal cancer is not bad that the rate of 5-years is 66.67% 
and 10-years is 44.44%.108 
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l Esophageal and gastric cancer 
 
Although their incidence is increased with respect to the general population, gastric 
and esophageal cancers are reported infrequently in most series of LT recipients96. 
Esophageal cancer following liver transplant is closely associated with history of 
alcohol intake and smoking chewing109. The factor risk of gastric cancer mainly is 
prolong time using immunosuppressive agent.  
 
Stage TNM of gastric cancer 
 
TX: The primary tumor cannot be evaluated. 
T0: There is no evidence of a primary tumor in the stomach. 
Tis: This stage describes a condition called carcinoma (cancer) in situ. The cancer 
is found only in cells on the surface of the inner lining of the stomach called the 
epithelium and has not spread to any other layers of the stomach. 
T1: The tumor has grown into the lamina propria, muscularis mucosae, or the 
submucosa, which are the inner layers of the wall of the stomach. 
T1a: The tumor has grown into the lamina propria or muscularis mucosae. 
T1b: The tumor has grown into the submucosa. 
T2: The tumor has grown into the muscularis propria, the muscle layer of the 
stomach. 
T3: The tumor has grown through all of the layers of the muscle into the connective 
tissue outside the stomach. It has not grown into the lining of the abdomen, called the 
peritoneal lining, or into the serosa, which is the outer layer of the stomach. 
T4: The tumor has grown through all of the layers of the muscle into the connective 
tissue outside the stomach. It has also grown into the peritoneal lining or serosa or the 
organs surrounding the stomach. 
T4a: The tumor has grown into the serosa. 
T4b: The tumor has grown into organs surrounding the stomach. 
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NX: Regional lymph nodes cannot be evaluated. 
N0: The cancer has not spread to the regional lymph nodes. 
N1: The cancer has spread to 1 to 2 regional lymph nodes. 
N2: The cancer has spread to 3 to 6 regional lymph nodes. 
N3: The cancer has spread to 7 or more regional lymph nodes. 
N3a: The cancer has spread to 7 to 15 regional lymph nodes. 
N3b: The cancer has spread to 16 or more regional lymph nodes. 
 
MX: Distant metastasis cannot be evaluated. 
M0: The cancer has not spread to other parts of the body. 
M1: The cancer has spread to another part or parts of the body. 
 
About stage group, stage 0 (Tis N0 M0); stage IA (T1 N0 M0); stage IB(T1 N1 M0), (T2 
N0 M0); stage IIA (T1 N2 M0), (T2 N1 M0), (T3 N0 M0); stage IIB (T1 N3a M0), (T2 N2 M0), (T3 
N1 M0), (T4b N0 M0); stage IIIA (T2 N3a M0), (T3 N2 M0), (T4a N1 M0), (T4b N0 M0); stage 
IIIB (T1 or T2 N3b M0), (T3 N3a M0), (T4a N3a M0), (T4b N1 or N1 M0); stage IIIC (T3 or T4a 
N3b M0), (T4b N3a or N3b M0); stage IV (any T or N, M1) 
 
Stage TNM and stage group of esophageal cancer110 
 
T, N, and M status, histologic grade and stage group definitions for esophagus and 
esophagogastric junction cancer in the 7th edition of the American Joint Committee on 
Cancer Staging Manual 
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                   Tab. 1.11: TNM stage of Gastric cancer 
 
              Tab. 1.12: Stage group of Gastric cancer 
Depend the stage, tumor location and situation of patient, therapy options include 
local mucosal resection or ablation therapies, esophagectomy, chemotherapy, and 
radiation therapy110. For gastric cancer, also can use regimen of therapy by surgical, 
chemotherapy and radiation therapy111. 
 
The survival of novo esophageal cancer is not high, with a mortality (combined for 
esophageal and gastric cancer of 62.5%) being second only to that of lung cancer96. 
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l Others novo neoplasia 
 
   Although it seems that breast cancer is no more frequent in LT compared to the 
general population, however, other studies have evidence that breast cancer incidence 
is in fact elevated in the transplant population, with the advantage, however, that early 
detection is more common, and this has also resulted in decreased mortality compared 
to that of the general population upon similar diagnose. The stage of breast cancer is 
complicated, including stage TNM and stage group96,112. 
 
TX: The primary tumor cannot be evaluated. 
T0: There is no evidence of cancer in the breast. 
Tis: Refers to carcinoma in situ. The cancer is confined within the ducts or lobules 
of the breast tissue and has not spread into the surrounding tissue of the breast. There 
are 2 types of breast carcinoma in situ: 
Tis (DCIS): DCIS is a noninvasive cancer, but if not removed it may develop into 
an invasive breast cancer later. DCIS means that cancer cells have been found in 
breast ducts and have not spread past the layer of tissue where they began. 
Tis (Paget’s): Paget’s disease of the nipple is a rare form of early, noninvasive 
cancer that is only in the skin cells of the nipple. Sometimes Paget’s disease is 
associated with another, invasive breast cancer. If there is another invasive breast 
cancer, it is classified according to the stage of the invasive tumor. 
 
T1: The tumor in the breast is 20 mm or smaller in size at its widest area. This is a 
little less than an inch. This stage is then broken into 4 substages depending on the 
size of the tumor: 
T1mi is a tumor that is 1 mm or smaller 
T1a is a tumor that is larger than 1 mm but 5 mm or smaller 
T1b is a tumor that is larger than 5 mm but 10 mm or smaller 
T1c is a tumor that is larger than 10 mm but 20 mm or smaller 
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T2: The tumor is larger than 20 mm but not larger than 50 mm. 
T3: The tumor is larger than 50 mm. 
T4: The tumor falls into 1 of the following groups: 
T4a means the tumor has grown into the chest wall. 
T4b is when the tumor has grown into the skin. 
T4c is cancer that has grown into the chest wall and the skin. 
T4d is inflammatory breast cancer. 
 
NX: The lymph nodes were not evaluated. 
N0: Either of the following: No cancer was found in the lymph nodes. Only areas of 
cancer smaller than 0.2 mm are in the lymph nodes. 
N1: The cancer has spread to 1 to 3 axillary lymph nodes and/or the internal 
mammary lymph nodes. 
N2: The cancer has spread to 4 to 9 axillary lymph nodes. Or it has spread to the 
internal mammary lymph nodes, but not the axillary lymph nodes. 
N3: The cancer has spread to 10 or more axillary lymph nodes. Or it has spread to 
the lymph nodes located under the clavicle, or collarbone. It may have also spread to 
the internal mammary lymph nodes. Cancer that has spread to the lymph nodes above 
the clavicle, called the supraclavicular lymph nodes, is also described as N3. 
 
MX: Distant spread cannot be evaluated. 
M0: The disease has not metastasized. 
M0 (i+): There is no clinical or radiographic evidence of distant metastases. 
Microscopic evidence of tumor cells is found in the blood, bone marrow, or other lymph 
nodes that are no larger than 0.2 mm. 
M1: There is evidence of metastasis to another part of the body, meaning there are 
breast cancer cells growing in other organs. 
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Tab. 1.13: Stage group of Breast cancer  
 
 
Due to the mentioned above, the stage TNM and stage group of kidney cancer and 
prostate cancer are not more detailed description. The incidence of prostate cancer 
does not seem to be increased in LT recipients, but the other genitourinary cancers 
(especially the renal cancer) seem to be higher than that of the general population. 
Mean time to diagnosis of non-prostate genitourinary cancer ranges from 20 to 55.3 
months, while in cases of prostate cancer the diagnosis is often performed between 
5.8 and 18.4 months after LT. In LT recipients, prostate cancer is more often diagnosed 
at earlier stages and has a good prognosis, whereas renal and bladder cancers have 
a poor prognosis96. 
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2. Hypothesis  
 
l The use of mTORi in patients with liver transplantation caused by HCC 
reduces the incidence of recurrence and increases the survival rate. 
 
l The use of mTORi in the patient after liver transplantation with de novo 
neoplasia reduces the incidence of recurrence and increasing the survival 
rate. 
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3. Objective  
 
1. To analyze if the use of mTORi in the patient with liver transplantation 
caused by HCC reduces the incidence of recurrence of HCC and increase 
the survival rate.  
 
2. To analyze if the use of mTORi in the patient with liver transplantation and 
“de novo” neoplasia reduces the incidence of recurrence and increase the 
survival rate.  
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4. Methods  
Clinical study with liver transplant recipients operated between 1990 and 2017 
because of HCC or liver transplants recipients with “de novo” neoplasia. The 
methodology of the work has followed the order of the hypotheses and objectives of 
the same. 
 
l To analyze if the use of mTORi in the patient with liver transplantation caused by 
HCC reduces the incidence of recurrence of HCC and increase the survival rate.  
 
l To analyze if the use of mTORi in the patient with liver transplantation and “de 
novo” neoplasia reduces the incidence of recurrence and increase the survival 
rate.  
 
This was an observational, retrospective cohort study, using a sample of patients 
drawn from all 1273 liver transplant patients at the Virgen del Rocío Hospital between 
March 1990 and July 2017. Of these, 433 patients were selected. 
 
 
 
Tab. 4.1. The patients selection 
The patients' data were conformed to analysis (n=392)
The patients with HCC recurrent(n=247) The patients with de novo neoplasia(n=171)
The patients were conformed the conditions inclusion (n=433)
The patient died cause by post-
transplantation(n=41)
The patients were living after 
transplantation(n=392)
All patients with OLT between 1990 and 2017 en HBPT (n= 1273)
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The table 1. describes how to conformed the patients and the types of patients for 
analysis. The patients conformed the conditions inclusion were 433. More than 90% of 
these patients were selected. 41 patients died post-transplantation, so were excluded. 
In these 392 patients, 247 patients were diagnosis with HCC and recurrent HCC. And 
there are 171 patients with de novo neoplasia. 
 
About patients  
In the tables below is shown the distribution of patients 
 
 
Gender of patients 
Gender Frequency Percentage 
Male 371 85.70% 
Female 62 14.30% 
 
The male patients were 6 times of female patients, it may caused because of alcohol 
intaking and smoke usually happens in the population male. 
 
Gender of patients whit HCC and de novo neoplasia(NN) 
Gender Frequency(HCC) Percentage(HCC) Frequency(NN)  Percentage(NN) 
Male 211 85.40% 148 86.55% 
Female 36 14.60% 23 13.45% 
Total 247 100% 171 100% 
Tab. 4.2. and Table 4.3. The distribution of gender of patients 
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Without the patients exclusion, the proportion of male/female in the patients with HCC 
and the patients de novo neoplasia are almost same that the male patients are 7 times 
of female. And the p > 0,05. 
 
 
Cirrhosis etiology 
Type Frequency Percentage 
Alcoholic Cirrhosis 245 56.60% 
CHVC 93 21.46% 
CHVB 57 13.16% 
Others 38 8.78% 
Total 433 100% 
 
Cirrhosis etiology of patients with HCC and the patients with de novo neoplasia(NN)  
Type Frequency(HCC) Percentage(HCC) Frequency(NN) Percentage(NN) p 
Alcoholic 
Cirrhosis 
134 54.25% 112 65.50% >0,05 
CHVC 66 26.72% 18 10.52% >0,05 
CHVB 33 13.36% 19 11.11% >0,05 
Others 14 5.67% 22 12.87% >0,05 
Tab. 4.4. and Table 4.5. The distribution of diagnosis 
 
Most of HCC were caused by alcoholic cirrhosis, also hepatitis virus B and C can 
affect HCC too. Obviously, there are some other cause in the table. 4, but there are 
rare cases which were less than 10% of it.  
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Distribution of age of the patients 
Age Frequency Percentage 
20-50 75 19.40% 
51-60 197 49.90% 
61-70 120 30.70% 
Tab. 4.6. The distribution of age of patients at the moment of liver transplant 
 
Most patients who make the operation of transplantation were between 51-60 years, 
and the mean was 56.04 years old.  
 
 
Blood group  
Type Frequency Percentage 
O 162 37.40% 
A 187 43.20% 
B 60 13.80% 
AB 24 5.60% 
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Fig. 4.1 
Tab. 4.7. and Fig 4.1. The distribution of Blood Group 
 
 
Blood group of the patients with HCC and patients with de novo neoplasia(NN) 
Type Frequency(HCC) Percentage(HCC) Frequency(NN) Percentage(NN)  p 
O 97 39.27% 61 35.68% >0,05 
A 106 42.91% 71 41.52% >0,05 
B 34 13.77% 28 16.37% >0,05 
AB 10 4.05% 11 6.43% >0,05 
Tab. 4.7-8. and Fig. 4.1. The distribution of Blood group 
 
 
Smoke 
Type of smoke Frequency Percentage 
Yes 287 66.30% 
No 146 33.70% 
O
37%
A
43%
B
14%
AB
6%
Blood group
O A B AB
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Fig. 4.2 
Tab. 4.9 and Fig 4.2. Distribution of smoking in patients of study 
 
Distribution of smoke in patients with HCC and NN 
Type Frequency(HCC) Percentage(HCC) Frequency(NN) Percentage(NN) 
Yes 170 68.80% 121 70.80% 
No 77 31.20% 50 29.20% 
Tab. 4.9-10. and Fig. 4.2. The distribution of smoke in patients 
 
In general, the patients with smoke is 2 times higher than without it. There are no 
difference between HCC and de novo neoplasia patient. 
 
 
 
 
 
 
Yes
66%
No
34%
Smoke
Yes No
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Alcohol  
Type Frequency Percentage 
Yes 278 64.20% 
No 154 35.60% 
 
Distribution of alcohol in patients with HCC and NN  
Type Frequency(HCC) Percentage(HCC) Frequency(NN) Percentage(NN)   p 
Yes 168 68% 116 67.80% >0,05 
No 79 32% 55 32.20% >0,05 
Tab. 4.11-12. The distribution of alcohol in patients 
 
As mentioned above, the patient who smoking always intaking alcohol. There are 
no difference between HCC and de novo neoplasia. 
 
Organ appearance 
Type Frequency Percentage 
Optimum 303 70% 
Suboptimal 130 30% 
Tab. 4.13. The organ appearance of donor 
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En these patients, there are 247 patients with HCC recurrent, and 171 patients with 
de novo neoplasia after liver transplantation. Including colorectal cancer, lung cancer, 
kidney cancer et.al.  
 
The distribution of de novo neoplasia 
Type of cancer Frequency Percentage 
Lung cancer 28 16.37% 
Colorectal cancer 8 4.68% 
Urothelial cancer 4 2.34% 
Esophagus cancer 1 0.58% 
Pancreatic cancer 2 1.17% 
Small bowel cancer 2 1.17% 
Hepatic sarcoma 1 0.58% 
Otorhinolaryngologic 
cancer 
31 18.13% 
Lymphoproliferative 
syndrome 
14 8.19% 
Breast cancer 6 3.51% 
Prostate cancer 10 5.85% 
Kidney cancer 4 2.34% 
Skin cancer 55 32.16% 
Gastric cancer 3 1.75% 
Central nervous cancer 1 0.58% 
Cholangiocarcinoma 1 0.58% 
Tab. 4.14. The types of cancer in de novo neoplasia 
 
In the patients with de novo neoplasia, there are 69 patients with tumor recurrence. 
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Immunosuppressive 
agent 
Frequency Percentage 
mTORi 152 35.1% 
CNI 255 58.9% 
MMF 26 6% 
Tab. 4.15. Distribution of immunosuppressive agent 
 
Immunosuppressive 
agent 
Frequency Percentage 
mTORi 86 34.8% 
CNI 158 1.2% 
MMF 3 64% 
Tab. 4.16. Immunosuppressive agent use in HCC 
 
 
Immunosuppressive 
agent 
Frequency Percentage 
mTORi 77 45% 
CNI 69 14.6% 
MMF 25 40.4% 
Tab. 4.17. Immunosuppressive agent use in “de novo” neoplasia 
 
 
 
Clinical study variables  
 
The criteria of safety assessment, and efficacy were determined after the follow-up 
many years. We record the side effects of mTORi. 
 
 106 
The efficacy variables of the preservation of de novo neoplasia: 
 
 
1. Survival  
2. Recurrence rate. 
 
 
Statistical analysis of clinical study  
For the purposes of the present analysis, the data were extracted from the 
database in the form of cohorts for both CNI and mTORi (including Sirolimus and 
Everolimus). From the clinical and demographic point of view, the data collected were: 
age, sex, etiology of liver disease, presence of hepatocellular carcinoma, alcohol, 
smoke, date of transplant, cancer stage, date of diagnosis de novo neoplasia, Child-
Pugh, MELD Score. And a complete history of immunosuppressive medication 
including terms and duration of treatment with mTORi was also obtained. 
 
The analyzes were performed with the IBM SPSS Statistics version 23.0 program. 
we have performed descriptive statistics of the study variables. For this we have used 
absolute frequencies and percentage in the case of qualitative variables. The 
quantitative variables will be summarized by Md (SD) (mean, standard deviation) and 
range (minimum and maximum) or P50 [P25 - P75] (median, interquartile range), 
depending on the degree of asymmetry of the same. The comparison of the qualitative 
variables was carried out by means of analysis with Chi2 text. And the survival analysis 
has been carried out with the nonparametric Kaplan-Meier method. 
 
A value of P <0.05 was considered statistically significant, using the two-tailed test. 
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5. Results 
 
5.1. Hepatocellular carcinoma(HCC) 
 
5.1.1. Influence of smoking and alcohol consumption  
 
 
 
Figure 5.1. The survival rate of smoke in patients with HCC (unit: month)  
 
We use the test Kaplan-Meier (p=0.670, p>0.05), in the short-term, the influence of 
smoke in survival is not clear. But in the long-term, the survival rate of patient without 
smoke is better. 
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Figure 5.2. The survival rate of alcohol in patients with HCC (unit: month)  
 
Also make the test to confirm the survival rate of alcohol intaking. And with the 
p=0.035 (p<0.05). For intaking alcohol, whatever short-term or long-term, no intake 
alcohol is much better than alcoholic intake. More than 60% patients without alcohol 
intaking and theirs’ survival time can achieve to 300 months, lees than 20% patients 
with alcohol intaking can reach to 200 months. 
 
 
5.1.2. Histological Findings 
 
There 247 patients with the diagnosis HCC, and the study has mentioned the 
distribution of gender, type of cirrhosis, blood group, smoke and alcohol of patients in 
the part method. But the study also describe the others side of HCC. Like the vascular 
invasion, capsule appearance and the differentiated of HCC. 
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Vascular invasion 
 Frequency Percentage 
Percentage 
valid 
Percentage 
accumulated 
Valid NO 206 83.4 83.4 83.4 
SI 41 16.6 16.6 100.0 
Total 247 100.0 100.0  
Table 5.1. The distribution of Vascular invasion in patients with HCC  
 
 
Figure 5.3. vascular invasion  
 
The Table 5.1. and figure 5.3. shown the patients with HCC and the distribution of 
Vascular invasion. 
 
Yes
17%
No
83%
Vascular invasion
Yes No
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Figure 5.4. The survival rate of Vascular invasion in patients with HCC (unit: month)  
 
With the test (p<0.0001, p<0.05) Kaplan-Meier, known about the related between 
survival time and the vascular invasion, almost 80% patients without vascular invasion 
reach 50 months, and more than 60% patients reach 150 months. However, just 40% 
patients can reach 220 months. Other side, less than 50% patients with vascular 
invasion can reach 50 months, and the largest time of survival is 183 months, just 3 
(7.3%)patients’ survival are more than 150 months. 
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Capsule appearance 
 Frequency Percentage 
Percentage 
valid 
Percentage 
accumulated 
Valid NO 
215 87.0 87.0 87.0 
SI 
32 13.0 13.0 100.0 
Total 
247 100.0 100.0  
Table 5.2. The distribution of capsule appearance in patients with HCC  
 
 
Figure 5.5. capsule appearance of HCC 
 
With the table 2. and the figure 5. Just 32 patients with capsule appearance. In the 
figure 6. (Test Kaplan-Meier, with p<0.0001, <0.05)shown the patients without capsule 
appearance, the survival time is much better than the patients with capsule 
Yes
13%
No
87%
Capsule appearance
Yes No
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appearance. More than 60% patients without it achieve 150 months after liver 
transplantation, however, the patients with it just 1 patient’s (3.12%) survival time more 
than 150 months. Most of these patients with it, the survival time is about 50 months 
 
 
Figure 5.6. The survival rate of Capsule appearance in patients with HCC (unit: 
month)  
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Edmondson 
 
Frequenc
y 
Percentag
e 
Percentage 
valid 
Percentage 
accumulated 
Valid High 
differentiated 
36 14.6 14.6 14.6 
Moderately 
differentiated 
189 76.5 76.5 91.1 
Poorly 
differentiated 
22 8.9 8.9 100.0 
Total 247 100.0 100.0  
Table 5.3. The differentiated of HCC  
 
 
 
Figure 5.7. The percentage of Edmondson of HCC  
 
Highly 
differentiated
15%
Moderately 
differentiated
76%
Poorly 
differentiated
9%
Edmonson
Highly differentiated Moderately differentiated Poorly differentiated
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Figure 5.8. The survival rate of Edmondson in patients with HCC(unit: month)  
 
With the table. 3 and figure. 7, can shown directly the distribution of the 
differentiated of cancer in patients. The figure 8. is the test Kaplan-Meier with p=0.090 
(p>0.05). In general, the tumor with highly differentiated is much better than poorly 
differentiated. The moderately differentiated is between those. 
 
5.1.3. Tumor recurrence 
 
247 patients with the diagnosis HCC, and there are 42 patients occur HCC recurrent, 
26 of it were metastasis.  
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Tumor recurrence 
 Frequency 
Percentag
e 
Percentage 
valid 
Percentage 
accumulated 
Valid NO 205 83.0 83.0 83.0 
SI 42 17.0 17.0 100.0 
Total 247 100.0 100.0  
Table 5.4. HCC recurrence in patients  
 
 
Figure 5.9. The percentage of HCC  
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Figure 5.10. Survival rate of patients with and without recurrence.(unit: month)  
 
We use test Kaplan-Meier to confirm the survival rate of recurrence tumor 
(p<0.0001, p<0.05). The survival rate of patients without HCC recurrent is higher than 
the patients with HCC recurrent. And 40% of these can achieve 300 months. 
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Figure 5.11. The distribution of location of recurrent  
 
 
 
Figure 5.12. The survival rate of the location of recurrent tumor (unit: month)  
 
No
83%
Local
7%
Metastasis
10%
Location of recurrent
No Local Metastasis
 120 
Due to the figure 11. Most recurrence are metastasis. But in the figure 12 (test with 
p<0.0001, p<0.05), the patients without recurrence and the survival time are much 
better than other two. About 70% patients reach 150 months (12.5 years), more than 
80% patients achieve 50 months, 40% patients’ survival time more than 200 months. 
60% patients with recurrent tumor in location local can reach 50 months, but the 
patients with metastasis just 30% of these can reach 50 months. 
 
5.1.4. Immunosuppressant scheme 
 
There are 158 patients use CNI, 86 patients with mTORi (37 patients use Sirolimus 
and 49 patients use Everolimus) and 3 patients with mycophenolate.  
 
mTORi, CNI, MMF 
 Frequency Percentage 
Percentage 
valid 
Percentage 
accumulated 
Valid mTORI 86 34.8 34.8 34.8 
CNI 158 64.0 64.0 98.8 
MMF 3 1.2 1.2 100.0 
Total 247 100.0 100.0  
Table 5.5. The use of immunosuppressive inhibitor  
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Figure 5.13. The survival of patients transplanted because of HCC in function of 
immunosuppressant regimen  
 
 
Figure 5.14. The survival rate of patients with CNI, mTORi and MMF. (unit: month)  
mTORi
35%
CNI
64%
MMF
1%
mTORi-CNI-MMF
mTORi CNI MMF
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The figure 14. is describe the survival rate by test Kaplan-Meier with the p=0.051. 
To the patients after liver transplantation, the effective of mTORi is better than CNI. 
More than 80% patients’ survival time beyond 50 months who used mTORi. The 
patients with CNI, about 70%, even less than 70% achieve 50 months. 60% patients 
with mTORi achieve 200 months, less than 40% patients with CNI reach 200 months 
and rare patients’ survival time reach 250 months.  
 
 
 
Figure 5.15. The distribution of patient used immunosuppressant with or without HCC 
recurrence. 
 
   In the figure 5.15. we can see 42 patients with HCC recurrence (18 patients with 
mTORi, 23 patients with CNI and 1 patient with MMF). (p=0.337) 
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SRL and EVR 
 Frequency Percentage 
Percentage 
valid 
Percentage 
accumulated 
Valid  161 65.2 65.2 65.2 
SRL 37 15.0 15.0 80.2 
EVR 49 19.8 19.8 100.0 
Total 247 100.0 100.0  
Table 5.6. Compare the Sirolimus and Everolimus in patients use mTORi 
 
 
Figure 5.16. The survival of patients about distribution of mTORi (Sirolimus and 
Everolimus) 
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 124 
 
Figure 5.17. The survival rate of patients use Sirolimus and Everolimus (unit: month) 
 
In the 86 patients use mTORi, there are 37 patients use Sirolimus and 49 patients 
use Everolimus. Figure 16. compare these two inhibitor’s effect and the survival time. 
The test with the p=0.018 (p<0.05). Due to the test and the figure, the effect of 
Everolimus is better than Sirolimus. The most difference is in the point 100 months, 
about 40%, but continue to 125 months, the difference is about 20%.  
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Figure 5.18. The survival rate of the patients with and without CNI. (unit: month)  
 
Also making the survival test to the patients with and without CNI’s therapy. This test 
with the p=0.025 (p<0.05). The test shown directly that the patients without CNI’s 
therapy is better than with CNI’s therapy, although there are rare patients’ survival time 
larger than 250 months with CNI. 
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Figure 5.19. The survival rate of the patients with and without steroid therapy. (unit: 
month)  
 
Steroid therapy also is a way to control the rejection reactive. We use the survival 
test (Kaplan-Meier, with the p=0.018 (p<0.05)) to compare the result of with and 
without steroid therapy. Same to the CNI’s therapy, the patients without steroid therapy 
is better than with steroid therapy. 
 
 
We also make the multivariate test to confirm the results, in the Tab. 5.7. we can 
see the valor of these variables. 
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Multivariate test 
Effect Valor 
mTORi, CNI, MMF p<0.0001 
SRL, EVR p=0.411 
Alcohol p=0.116 
Smoke p=0.068 
Stage T p<0.0001 
Stage N p<0.0001 
Stage M p<0.0001 
Stage group p<0.0001 
Vascular invasión p=0.259 
Capsule appearance p=0.003 
Edmondson p=0.053 
Steroid p<0.0001 
CNI p=0.041 
Location of recurrence p=0.622 
Tab. 5.7. The result of Multivariate test. 
 
 
84 patients were died. And 34 caused by cancer(HCC), 6 patients died by 
cardiovascular diseases related with HCC (Tab. 5.8-9. And Figure. 5.19). 
 
DEATH 
 Frequency Percentage 
Percentage 
valid 
Percentage 
accumulated 
Valid NO 163 66.0 66.0 66.0 
SI 84 34.0 34.0 100.0 
Total 247 100.0 100.0  
Tab. 5.8 
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Figure. 5.20 
 
CAUSE OF DEATH 
 Frequency Percentage 
Percentage 
valid 
Percentage 
accumulated 
Valid  171 69.2 69.2 69.2 
CANCER 34 13.8 13.8 83.0 
POST-OLT 1 .4 .4 83.4 
CARDIOVASCUL
AR 
6 2.4 2.4 85.8 
OTHERS 35 14.2 14.2 100.0 
Total 247 100.0 100.0  
Tab. 5.9 
 
 
 
 
No
66%
Si
34%
Exitus
No Si
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5.2. De novo neoplasia (NN) 
 
 
 
Figure 5.21. The survival rate of smoke in patients de novo neoplasia. (unit: month) 
 
We use the test survival (Kaplan-Meier, with p=0.001) to check the related of smoke 
and survival time in patients de novo neoplasia. Different with related HCC and smoke, 
the smoke and the novo neoplasia is clearly that without smoke is much better than 
smoker.  
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Figure 5.22. The survival rate of alcohol in patients with de novo neoplasia. (unit: 
month)  
 
Use the test Kaplan-Meier, with the p=0.020. Intaking alcohol has bad effect for 
patients.  
 
 
Tumor recurrence 
 Frequency Percentage 
Percentage 
valid 
Percentage 
accumulated 
Valid NO 102 59.6 59.6 59.6 
YES 69 40.4 40.4 100.0 
Total 171 100.0 100.0  
Table 5.10. Recurrent tumor in patients with de novo neoplasia  
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Figure 5.23. The distribution of recurrent tumor in the patients with NN.  
 
In figure 5.24. we can observe the survival of patient in case of tumor recurrence 
in patients with NN. 
 
Figure 5.24. The survival rate of recurrent tumor in patients with NN. (unit: month)  
Yes
40%
No
60%
Recurrent tumor
Yes No
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There are 69 patients (40%) occur tumor recurrence. And use the survival test to 
check the related with recurrence and survival time, the Kaplan-Meier test (p<0.0001) 
shown the survival time. Without recurrence is more than 4 times than with it in the 
point 50 months. And in the point 200 months, without recurrence is almost 6 times 
than with it. 
 
In next table we can see what treatment was offered to patients with NN: 
surgical resection or chemotherapy/radiotherapy.  
 
Treatment way 
Type of treatment Frequency Percentage 
Resection 89 52.05% 
QT or RT 47 27.49% 
No treatment 35 20.46% 
Total  171 100% 
Table 5.11. The frequency and percentage of treatment way in patients with NN.  
 
 
Figure 5.25. The distribution of treatment way (QT-RT means: Chemotherapy or 
Radiotherapy)  
No treatment
20%
Resection
52%
QT or RT
28%
Treatment way
No treatment Resection QT or RT
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We have studied (figure 5.26) the survival of patients with NN in case of treatment 
way (QT-RT means: Chemotherapy or Radiotherapy).  
 
 
 
Figure 5.26. The survival rate of the treatment way in patients with NN. (unit: month)  
 
In the table 2 and figure 5, described the distribution of treatment way in patients 
with NN. With the survival test (p<0.0001), the resection is the best way to treatment 
tumor in NN. Chemotherapy or Radiotherapy and without treatment is similar, but 
Chemotherapy or Radiotherapy is little better than without treatment in the short-term. 
 
In next figure we can observe survival of transplanted patients with NN in function 
of tumor size (T stage). 
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Figure 5.27. The survival rate of Stage T in patients with NN. (unit: month) 
(p<0.0001) 
 
Obviously, the survival time of stage 1 of T is best. As we know, the stage 4 is 
severe, so the worst is stage 4, the stage 2 and stage 3 are similar but the stage 2 is 
better than stage 3. 
 
Next figure shows the same in case of metastatic nodes (N stage) and distance 
metastasis (M stage). 
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Figure 5.28. The survival rate of Stage M in patients with NN. (unit: month) 
(p<0.0001)  
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Figure 5.29. The survival rate of Stage M in patients with NN. (unit: month) 
(p<0.0001)  
 
The figure 5.28. is shown clearly that stage 0 of N is the best. And the figure 5.29. 
show the without metastasis distal, the survival time is larger. 
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Figure 5.30. The survival rate of Stage group in patients with NN. (unit: month) 
(p<0.0001)  
 
In the general, the stage 1 is better than others, although the rate of stage 2 higher 
than stage 1 twice.  
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Figure 5.31. The survival rate of died cause in patients with NN. (unit: month), 
(p<0.0001)  
 
 
The blue line is the rate of patients alive. There are 25 patients died by other cause, 
6 patients by cardiovascular and 58 patients by cancer. Cancer kills patients before 
than cardiovascular diseases. 
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mTORi-CNI in NN 
Type Frequency Percebtage 
mTORi 77 45.00% 
CNI 69 40.40% 
MMF 25 14.60% 
Table 5.12. The distribution of inhibitor used in patients with NN  
 
In next figure we can observe the survival of patients with NN depending of 
immunosuppressant treatment. 
 
 
Figure 5.32. The survival rate of CNI, mTORi and MMF in patients with NN. (unit: 
month)  
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With the p=0.058, the survival test shown that mTORi and MMF are better than 
CNI. In the short-term, MMF is similar with CNI, and mTORi is better than others two. 
In the middle-term, the MMF is the best in these 3 inhinitor, however, later than 80 
months, the effect of MMF is worse than mTORi. CNI is the worst in these 3 treatment. 
 
 
 
Sirolimus VS Everolimus 
Type of mTORi Frequency Percentage 
Sirolimus 54 70.13% 
Everolimus 23 29.87% 
Total 77 100.00% 
Table 5.13. The mTORi distribution in patients with NN  
 
In next figure (figure 5.32.), we show the survival in case of type of mTORi in 
patients with NN. 
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Figure 5.33. The distribution of mTORi in the patients with NN.  
 
 
 
Figure 5.34. The survival rate of mTORi in patients with NN. (unit: month)  
70%
30%
SIR-EVE
Sirolimus Everolimus
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Compare in these two inhibitor. Due to the Kaplan-Meier test (with the p=0.042), 
the effect of Everolimus is better than Sirolimus. And theirs different is about 10%. 
 
 
Skin cancer 
 
 
Figure 5.35. The survival rate of CNI, mTORi and MMF used in patients with skin 
cancer. (unit: month) (p=0.945)  
 
For the skin cancer, the advantage of these 3 is not clearly, in the first 50 months, 
the MMF is better than others two; between the 75 months and 120 months, the CNI 
is better than others; and after 120 months, the mTORi shown better effect. 
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Figure 5.36. The survival rate of Sirolimus and Everolimus in patients with skin 
cancer. (unit: month) (p=0.886)  
 
There is no difference in survival of skin cancer between Everolimus or Sirolimus 
(p > 0.05) 
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Figure 5.37. The distribution of patient used immunosuppressant with or without 
tumor recurrence.(p=0.590) 
 
 
There are 22 patients with skin cancer used immunosuppressant mTORi, the 
survival of with tumor recurrence is higher. But only 2 patients with tumor recurrence, 
and this test dose not has statistical significance. (p=0.440) 
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Figure 5.38. The survival rate of CNI used in patients with skin cancer. (unit: month) 
(p=0.883)  
 
Also, there is no difference in survival in case of CNI treatment. 
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Figure 5.39. The survival rate of steroid used in patients with skin cancer. (unit: 
month) (p=0.003)  
 
 
Without steroid therapy is much better than patient with the steroid therapy. 
 
 
 
 
 
 
 
 
 
 
 147 
ORL cancer 
 
In next figure we can observe survival of ORL cancer patients depending of 
treatment used, surgical resection VS chemotherapy/radiotherapy. 
 
 
Figure 5.40. The survival rate of treatment way in patients with Otorhinolaryngologic 
cancer. (unit: month) (p=0.030)  
 
As we can observe, surgical resection gives a better survival in patients with ORL 
cancer. 
Next figure shows survival in function of immunosuppressant regimen we used in 
these patients, mTORi, CNI or MMF. 
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Figure 5.41. The survival rate of CNI, mTORi and MMF used in patients with 
Otorhinolaryngologic cancer. (unit: month) (p=0.018)  
 
The MMF treatment is better than mTORi and CNI. Also, mTORi is better than CNI. 
(p<0.05) 
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Figure 5.42. The distribution of patient used immunosuppressant with or without 
tumor recurrence. 
 
 
There are 22 patients without tumor recurrence (11 patients with mTORi, 9 patients 
with CNI and 2 patients with MMF), and 9 patients with tumor recurrence. (p=0.020) 
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Figure 5.43. The survival rate of CNI used in patients with Otorhinolaryngologic 
cancer. (unit: month) (p=0.086)  
 
Without CNI’s therapy is better than CNI therapy. 
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Figure 5.44. The survival rate of CNI used in patients with Otorhinolaryngologic 
cancer. (unit: month) (p=0.159)  
 
Everolimus seems to be better than Sirolimus, but it is only a clinical observation 
without statistical significance. (p>0.05) 
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Lung cancer 
 
In figure 5.45. we can see survival of lung cancer depending no treatment offered: 
palliative, chemotherapy/radiotherapy or surgical resection. 
 
 
Figure 5.45. The survival rate of treatment way in patients with lung cancer. (unit: 
month) (p=0.005)  
 
The resection is the best than others 2 treatment way. Without treatment is the 
worst way, and cannot reach 15 months. 
 
Next figures show survival of patients with lung cancer depending of 
inmunosupressant regimen. 
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Figure 5.46. The survival rate of CNI,mTORi and MMF used in patients with lung 
cancer. (unit: month) (p=0.067)  
 
mTORi is better than others 2 drugs CNI and MMF, although it is only a clinical 
observation with a little statistical signification (p<0,05). Survival time is largest that 
almost reach 50 months. 
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Figure 5.47. The distribution of patient used immunosuppressant with or without 
tumor recurrence. 
 
 
   There are 23 patients with tumor recurrence, 9 patients with mTORi regimen, 11 
patients with CNI regimen and 3 patients with MMF regimen. (p=0.238) 
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Figure 5.48. The survival rate of CNI used in patients with lung cancer. (unit: month) 
(p=0.910)  
 
There is no difference if we use or not use CNI in inmunosupressant regimen 
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Figure 5.49. The survival rate of mTORi used in patients with lung cancer. (unit: 
month) (p=0.001)  
 
There are 14 patients with lung cancer use mTORi, and with the figure 28. shown, 
Everolimus is much better than Sirolimus. Especially the survival time, with everolimus 
therapy is more than 2 times than patients with sirolimus. 
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Digestive cancer 
 
In next figures we can observe survival of patients with digestive cancer in function 
of immunosuppressant treatment we used. Due to the little number of patients with 
digestive cancer  (colorectal, stomach, esophagus) (n=14), we make the whole 
digestive system cancer together to make the test survival (Kaplan-Meier). 
 
 
Figure 5.50. The survival rate of inhibitor used in patients with digestive system 
cancer. (unit: month) (p=0.150)  
 
mTORi’s efficacy is the best of these 3 drugs. 
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Figure 5.51. The distribution of patient used immunosuppressant with or without tumor 
recurrence. 
 
   There are 6 patients with tumor recurrence (1 patient with mTORi, 4 patients with 
CNI and 1 patient with MMF), and 8 patients without tumor recurrence. (p=0.166) 
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Figure 5.52. The survival rate of CNI used in patients with digestive system cancer. 
(unit: month) (p=0.694)  
 
There is no difference in survival using or not CNI treatment. 
 
 
Because of all patients with digestive system cancer do not use the steroid, this 
survival test not present the compared of with and without steroid. 
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Figure 5.53. The survival rate of mTORi used in patients with digestive system 
cancer. (unit: month) (p=0.502)  
 
There are 6 patients with mTORi therapy, and only 1 patient use Everolimus, so 
difference cannot be analyzed. 
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Figure. 5.54. The survival rate of treatment way in patients with digestive cancer. (unit: 
month) (p=0.003) 
 
   With the figure 5.54. we can see the survival of surgical resection is the best, and 
in these patients, there is no one with chemotherapy or radiotherapy. 
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Lymphoproliferative syndrome (SLPT) 
 
Next figures shows difference in survival of liver transplant patients with SLPT 
depending of immunosuppressant regimen 
 
 
Figure 5.55. The survival rate of inhibitor used in patients with lymphoproliferative 
syndrome. (unit: month) (p=0.185)  
 
The mTORi is the best of these 3 inhibitor, although the largest survival time (more 
than 140 months) is in patient with CNI. These differences are with p>0,05 
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Figure 5.56. The survival rate of inhibitor used in patients with lymphoproliferative 
syndrome. (unit: month) (p=0.313)  
 
The survival rate of without CNI therapy is better than with it. (p>0.05) 
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Figure 5.57. The survival rate of steroid used in patients with lymphoproliferative 
syndrome. (unit: month) (p=0.254)  
 
There is 1 patient with steroid therapy, so this point cannot be analyzed. 
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Figure 5.58. The survival rate of mTORi used in patients with lymphoproliferative 
syndrome. (unit: month) (p=0.234)  
 
There are 7 patients use the mTORi and the efficacy of Everolimus in survival sems 
to be better than Sirolimus, although p>0,05 because of the few patients analyzed 
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Figure 5.59. The distribution of patient used immunosuppressant with or without tumor 
recurrence 
 
   There are 4 patients with tumor recurrence, and all the 4 patients with CNI regimen. 
(p=0.024) 
 
 
 
 
 
 
 
 
 
 
 167 
Breast cancer 
 
Next figures shows difference in survival of liver transplant women with breast 
cancer, depending of immunosuppressant regimen  
 
 
 
Figure 5.60. The survival rate of inhibitor used in patients with breast cancer. (unit: 
month) (p=0.082)  
 
There are 6 patients with breast cancer, 1 patient with CNI therapy, 3 patients with 
MMF therapy and 3 patients with mTORi therapy. In the survival test, the MMF and 
mTORi are similar, but MMF is better. The 6 patients without steroid therapy and all 
the 3 patients with mTORi were use Sirolimus. 
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Figure 5.61. The distribution of patient used immunosuppressant with or without 
tumor recurrence 
 
   There are 3 patient with tumor recurrence, 2 patients with mTORi regimen and 
other 1 patient with CNI regimen. (p=0.189) 
 
 
 
 
 
 
 
 
 
 169 
Urinary system cancer 
 
Next figures shows difference in survival of liver transplant patients with urinary 
system cancer (kidney cancer, urothelial cancer, prostatic cancer), depending of 
immunosuppressant regimen 
 
 
Figure 5.62. The survival rate of inhibitor used in patients with Urinary system cancer 
cancer. (unit: month) (p=0.100)  
 
In the survival test, the effective of mTORi (n=9) is the best, MMF (n=4) is between 
mTORi and CNI (n=5). This is only a clinical observation, with p near to 0.05. 
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Figure 5.63. The survival rate of CNI used in patients with Urinary system cancer 
cancer. (unit: month) (p=0.348)  
 
In the short-term (50 months), with CNI therapy is better, and after 50 months, 
without CNI therapy is better and the different is almost 40%. (p>0.05) 
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Figure 5.64. The survival rate of mTORi used in patients with Urinary system cancer 
cancer. (unit: month) (p=0.593)  
 
There are 2 patients with Everolimus and 7 patients with Sirolimus. In this survival test, 
the survival rate of patients with Everolimus is better than Sirolimus. (p>0.05) 
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Figure 5.65. The distribution of patient used immunosuppressant with or without tumor 
recurrence. 
 
 
   There are 2 patients with tumor recurrence and 16 patients without tumor 
recurrence. In these 2 patient, 1 with CNI and other with MMF. (p=0.316) 
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Hepatobiliary cancer 
 
Next figures shows difference in survival of liver transplant patients with HPB 
cancer, depending of inmunosupressant regimen  
 
 
 
Figure 5.66. The survival rate of inhibitor used in patients with Hepatobiliary cancer 
(without HCC). (unit: month) (p=0.515)  
 
There are 4 patients with hepatobiliary cancer, due to the HCC is a separate 
chapter. And in these patients, 3 patients with CNI and 1 with mTORi (Sirolimus). 
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Figure 5.67. The distribution of patient used immunosuppressant with or without tumor 
recurrence 
 
   All the 4 patients with hepatobiliary cancer have been recurrent tumor. 1 with 
mTORi regimen and others 3 patients with CNI regimen. 
 
Multivariant analysis of influence of mTORi in NN 
 
Effect Odds ratio 95% Confidence 
interval 
Valor (p) 
Skin cancer 1.8 1.6 – 2.5 0.19 
ORL cancer 2.5 1.2 – 2.4 0.05 
Lymphoproliferative 
syndrome 
4.8 2.8 – 7.2 0.03 
Digestive cancer 1.3 1.2 – 2.1 0.23 
Urinary cancer 4.6 3.2 – 6.8 0.04 
Breast cancer 0.7 0.6 – 0.9 0.36 
Tab. 5.14. 
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6. Discussion  
 
 
There are many study describing safety of mTORi as a immunosuppressant 
therapy after liver transplantation. Although the adverse effective of mTORi, including 
the distal edema, dermatological adverse effective, oral mucositis, diarrhea, abdominal 
pain etc., these drugs can be used to avoid rejection in these patients. 
 
mTORi reduce the incidence of the complications after operation liver 
transplantation including nephrotoxicity, neurotoxicity, hypertension and de novo DM. 
 
As we known, the de novo neoplasia is a important factor risk to affect the survival 
time in patient after liver transplantation because of immunotherapy drugs. And the 
patients after liver transplantation need to keep intake the immunosuppressive agent. 
So, how to control the dose or choose the type of immunosuppressive agent for find 
out the balance to make the patient have a better living after LT is the final objective 
that we want to reach.  
 
The treatment way is a important factor to survival. The most important therapy in 
survival of patients with cancer is resection or chemotherapy/radiotherapy. In liver 
transplant patients, immunosuppressant regiment could help or be worst for the 
curation of the tumor. In this study, most of patients is resection, the second is 
chemotherapy or radiotherapy and the worst way is no treatment. The survival time 
and rate of resection is very higher than others two. Why there are some patients 
without the treatment resection? It’s depend the situation of patient, the stage of cancer 
and the overall status. Some patients with the cancer in end-stage when founded or 
not meet the criteria of resection.  
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In liver transplant patients because of HCC or in those patients with “de novo” 
neoplasia, immunosuppressant treatment could be harmful for the treatment of the 
cancer. CNI and MMF have demonstrated reduce immunity in the patient and let the 
tumor grows. However, an anti-neoplastic activity has been demonstrated for 
everolimus with regard to various solid tumors (kidney cancer, lung cancer, …), and a 
potential role in HCC and cholangiocarcinoma are being increasingly reportrd113. 
 
In this study, we make an analysis of diverse factors that could have effect on the 
survival of patients with neoplasia de novo or those transplanted because an HCC, as 
smoke, alcohol, histological characteristic, treatment method and immunosuppressant 
scheme.  
 
This study analyzes the patients after liver transplantation with inhibitor CNI, mTORi 
and MMF. 
 
 
6.1. Hepatocellular carcinoma (HCC) 
 
6.1.1. Is there influence in survival about smoking and alcohol? 
 
 
We have observed that tobacco and alcohol reduce the survival time. In the short-
term, the effective of smoke is not clear, even the survival time of smoking patient is 
higher in the first 50 months. But in the long-term, the survival rate of patient without 
smoke is better. For intaking alcohol, whatever short-term or long-term, no intake 
alcohol is much better than alcoholic intake. More than 60% patients without alcohol 
intaking and theirs’ survival time can achieve to 300 months, lees than 20% patients 
with alcohol intaking can reach to 200 months. So, smoking and alcohol consumption 
reduce the survival time. There are some studies published also describe the influence 
of smoking and alcohol for HCC, that smoking and alcohol consumption increase the 
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risk of HCC occur114,115. And there is a study indicate that smoking and alcohol 
consumption after liver transplantation can reduce the survival time116. 
 
 
6.1.2. Do histological characteristics affect patient survival?  
 
About the histological characteristic, including the vascular invasion, capsule 
appearance and Edmondson. We observe the related of survival time and vascular 
invasion, almost 80% patients without vascular invasion reach 50 months, and more 
than 60% patients reach 150 months. However, just 40% patients can reach 220 
months. Other side, less than 50% patients with vascular invasion can reach 50 
months, and the largest time of survival is 183 months, just 3 (7.3%) patients’ survival 
are more than 150 months. The patients without capsule appearance, the survival time 
is much better than the patients with capsule appearance. More than 60% patients 
without it achieve 150 months after liver transplantation, however, the patients with it 
just 1 patient’s (3.12%) survival time more than 150 months. Most of these patients 
with it, the survival time is about 50 months. Other point worth to attention, about the 
Edmondson. As we known, to the survival time and prognosis, the highly differentiated 
tumor will be the be better, and the poorly differentiated tumor is bad. But there is a 
unusual survival rate in our analysis that the poorly differentiated is higher than the 
moderately differentiated and the highly differentiated at the first few months, although 
back to the usual situation few months later. May in the first few months, the effective 
is not clearly or the patients with poorly differentiated is not enough. In several studies 
indicate that vascular invasion is related to poor prognosis and HCC with vascular 
invasion have a higher recurrence rate117. Same to the vascular invasion, the capsule 
appearance and Edmondson are the factor risk to reduce the survival time and 
increase the recurrence rate117,118. 
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6.1.3. Survival in the patients with recurrence of HCC 
 
In this study, there are 17% patients with recurrence of HCC. Of these patients, 82% 
patients are HCC without recurrence, 10% patients occur with metastasis and 7% 
patients occur with local recurrence without metastasis. The survival rate of patients 
without recurrence of HCC is higher than the patients with recurrence of HCC. And 40% 
of these can achieve 300 months. Due to mentioned above, smoking, alcohol 
consumption and the histological characteristics have influence in recurrence of HCC. 
In spite of this, HCC’s recurrence is a complicated situation with many factors and 
causes. Also there are several articles point out that the influence of HCC’s recurrence 
to the survival of patients after liver transplantation119,120. 
 
At the same time, we make the comparing of the location of HCC’s recurrence. The 
patients without recurrence and the survival time are much better than other two. About 
70% patients reach 150 months (12.5 years), more than 80% patients achieve 50 
months, 40% patients’ survival time more than 200 months. 60% patients with 
recurrent tumor in location local can reach 50 months, but the patients with metastasis 
just 30% of these can reach 50 months. There is a article describe about the location 
of HCC’s recurrence and the survival time. Same to our result, the survival time of HCC 
recurrence is better than HCC recurrence with metastasis119. 
 
 
 
6.1.4. Is there influence of survival about Immunosuppressant scheme? 
 
According to data from the Spanish Hepatic Transplant Registry (RETH), 
Hepatocellular Carcinoma is one of the main indications for transplantation in Spain, 
reaching more than 20% of annual transplants. Likewise, and being the only organ that 
transplants a type of cancer, the immunosuppressive management in these patients 
should be peculiar and especially individualized. 
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Based on retrospective studies, a direct correlation was found between high levels 
of calcineurin inhibitors (CNI) in the first months post-transplant and the risk of tumor 
recurrence in transplant patients according to the Milan criteria. Therefore, it is 
advisable to avoid overdosing of the CNI, these levels oscillating in: Tacrolimus <10 
ng / ml and Cyclosporine <300 ng / ml. 
 
In relation to Hepatocellular carcinoma (HCC), two possible immunosuppression 
scenarios are proposed: 
 
A.- Role of mTORi in the prevention of HCC relapse: 
 
Several retrospective studies and systematic reviews show that mTORi reduce the 
risk of tumor recurrence in patients with HCC. However, the scientific evidence is very 
low. 
 
The use of mTOR inhibitors in high-risk patients has been generalized in clinical 
practice (Alpha-Fetoprotein> 200ng / ml, HCC exceeding the Milan Criteria in the 
explant piece, vascular invasion, poorly differentiated tumor) . In spite of this, it has not 
been demonstrated that this clinical practice supposes a benefit for the patient. 
 
There is not enough scientific evidence to recommend the widespread use of 
mTOR inhibitors to reduce the risk of recurrence after liver transplantation. 
 
B.- Role of mTOR inhibitors in the treatment of CHC relapse: 
 
There is no evidence that the use of mTORi improves the prognosis of patients with 
HCC relapse. 
 
There are small series in which the combination of mTORi and sorafenib has been 
used safely. There are no clinical trials that demonstrate a survival benefit. 
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To the patients after liver transplantation, the effective of mTORi is better than CNI. 
More than 80% patients’ survival time beyond 50 months who used mTORi. The 
patients with CNI, about 70%, even less than 70% achieve 50 months (p=0.051). 60% 
patients with mTORi achieve 200 months, less than 40% patients with CNI reach 200 
months and rare patients’ survival time reach 250 months. The MMF’s effective is the 
best, but only 3 patients with this regimen, so it is only a clinical observation without 
statistical confirmation. It is only a clinical observation without statistical confirmation.  
In the 86 patients use mTORi, there are 37 patients use Sirolimus and 49 patients use 
Everolimus. Due to the test, the effect of Everolimus is better than Sirolimus. The most 
difference is in the point 100 months, about 40%, but continue to 125 months, the 
difference is about 20%.(p=0.018)  
 
As mentioned in introduction that CNI as the main immunosuppressant for patients 
after liver transplantation in past years. Considering of the toxicities including: 
nephrotoxicity, neurotoxicity, hypertension, de novo DM and these adverse effecting 
can increase the incidence of de novo neoplasia. The new immunosuppressant had 
been developed: the mammalian target of rapamycin inhibitors (m-TORi). mTORi has 
a different mechanism to CNI, it reduce the incidence of de novo neoplasia and HCC 
recurrence121, and increase the survival after liver transplantation. In our study, the 
survival time of patients used mTORi are higher than CNI. CNIs have been 
documented to have adverse impact on cancer in in vitro and in vivo animal studies 
and to have dose related adverse impact on HCC recurrence and survival in clinical 
series121. 
 
Everolimus and Sirolimus are the two immunosuppressant belong to mTORi with 
similar mechanism, although they have different pharmacokinetic, pharmacodynamic 
and toxicodynamic properties. We make the comparing of effective of these two 
inhibitor and get the result that Everolimus’ effective is better than Sirolimus, but there 
is no article published compared the effective of survival in these two inhibitor, although 
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they describe the difference from other side such as renal function, dyslipidemia, 
hematology, edema and infections et. al.121.  
 
We also make the survival test of therapy with CNI or no and about Steroid. The 
result is that without CNI’s survival is better, same to Steroid. As the mentioned in 
introduction that Steroid is the choose in the early-phase liver transplantation and with 
many adverse effecting. It has been replaced by others drugs like CNI and mTORi. 
 
 
 
6.2. mTORi in “de novo” neoplasia after LT 
 
6.2.1. Do smoking and alcohol have influence on survival? 
 
Like the result of HCC, the survival of patients without smoke and alcohol is higher 
than with it. Smoke is the cause can affect many cancer such as lung cancer, 
otorhinolaryngologic cancer, and is the factor risk for cardiovascular disease. Same to 
smoke, alcohol consumption also is the factor risk of de novo neoplasia for patients 
after OLT and can increase the incidence of de novo neoplasia. There are several 
articles has been described that the alcohol consumption ant tobacco are well-known 
to be associated with these tumor because the carcinogenic or co-carcinogenic effects 
of smoking and drinking might be enhanced by the post-LT immunosuppressive 
therapy. And the active smoking was revealed as one of the major risk cofactors, 
independent of alcoholic relapse, of long-term morbidity and mortality in transplant 
recipients, either from cardiovascular complications or from de novo neoplasms. In 
general, the drinker usually is a smoker, because we now acknowledge that tobacco 
is a risk factor for alcohol abuse. So, smoke and alcohol intaking increase the incidence 
occurring of de novo neoplasia. There are several studies indicate in the last 10 years, 
alcohol liver disease is the LT indication that has seen the greatest increase in 
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prevalence as well as in post-LT survival rate compared with other causes of liver 
disease122,123. 
 
 
 
 
6.2.2. Is there influence in survival about treatment of the tumor? 
 
In our study, the resection is the best way to treatment tumor in de novo neoplasia, 
with a 45% of survival in 20 years (p=0). Chemotherapy or Radiotherapy and no 
treatment is similar, with no survival at 10 years, but Chemotherapy or Radiotherapy 
is little better than without treatment in the short-term. Due to the conditions of 
treatment, when the tumor has been advanced to end-stage or cannot be resection, 
medico should choose the chemotherapy or radiotherapy to reduce the stage of tumor 
till reach the criterion of resection. Or if the tumor is advanced or with metastasis distal, 
it may not get the result that hoped. Considering the socially side, doctor and the 
patient may choose no treatment. But there is not an article to discuss about this 
relation to LT patients. 
 
6.2.3. The influence in survival of cancer staging 
 
We make the analysis of the stage of cancer and get the result: about the stage T, 
the survival time of stage 1 of T is best. As we know, the stage 4 is severe, so the 
worst is stage 4, the stage 2 and stage 3 are similar but the stage 2 is better than stage 
3; about the stage N, the stage 0 with the best survival time and others are similar and 
bad; about the stage M, the survival time without metastasis distal is more better than 
with it. It’s well-known the effective about stage of cancer that N is describe the size of 
tumor, N about lymph node invasion and M is describe the metastasis distal. Whatever 
the novo neoplasia in patient after LT or general population, a tumor with metastasis 
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means the cancer has been entre end-stage or advanced and there are few treatment 
for this situation. Certainly the N and T stage mean the developing of the cancer. 
 
 
 
 
 
6.2.4. The influence of immunosuppressant treatment in neoplasia de novo. 
 
mTORi in “de novo” neoplasia after LT 
 
“De novo” neoplasms are an important cause of morbidity and mortality after liver 
transplantation. The recipients of transplants of solid organs have a greater risk of 
neoplasia than the general population. This is an important cause of mortality. 
 
In relation to de novo neoplasms, there are two possible scenarios in which to 
assess the role of immunosuppression:1) the possible changes in immunosuppression 
that can be carried out to try to prevent the development of de novo neoplasms and 2) 
the changes in the immunosuppression in patients who have developed neoplasms. 
 
The first action to try to avoid the development of de novo neoplasms should be to 
act on the risk factors of neoplasia such as smoking, alcohol or solar radiation, which 
are important risk factors both in the general population and in transplant patients 
(papers on tobacco, alcohol, solar radiation). Acting on these factors can reduce the 
risk of neoplasia, as shown by the fact that transplant patients who quit smoking have 
a lower risk of developing neoplasia (LT over tobacco). 
 
Several studies have evaluated the role of calcineurin inhibitors (CNI). Some 
studies suggest that patients treated with tacrolimus develop de novo neoplasms more 
frequently than those treated with cyclosporine, possibly due to the greater 
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immunosuppressive power of tacrolimus. There are also studies that attribute a greater 
oncogenic capacity to cyclosporine. In the absence of evidence, one or the other CNI 
cannot be recommended. 
 
The oncogenic role of antilymphocyte globulins (OKT3 and ATG) has been known 
for years. They favor the development of lymphomas and their use is associated with 
an increased risk of developing neoplasms in general (transplantation). Therefore, it is 
recommended to avoid its use. This recommendation does not affect antibodies 
against CD25. 
 
The inhibitors of mTOR (mammalian target of rapamycin) (mTORi) sirolimus and 
everolimus have antiproliferative capacity and are used as chemotherapeutic agents 
in cancer patients. For this reason, there has been much hope that 
immunosuppression using these drugs will reduce the risk of neoplasia. Patients 
receiving immunosuppression with mTORi have less risk of developing non-melanoma 
cutaneous neoplasms, both in liver transplantation and kidney transplantation, but this 
does not justify their use as immunosuppressants in all patients, since this type of 
injuries very rarely is fatal. The effect of these drugs on the development of non-
cutaneous neoplasms is much less clear. In clinical trials with several years of follow-
up and with important numbers of patients, no differences have been found in the 
incidence of non-cutaneous neoplasms between patients treated with mTORi and in 
patients who maintain treatment with CNI. 
 
It is not clear that the intensity of the immunosuppressive treatment is associated 
with a higher or lower prevalence of neoplasia. Some studies suggest that a more 
potent immunosuppressive treatment may predispose to an increased risk of neoplasia. 
On the other hand, some side effects of immunosuppression are dose-dependent, 
such as renal toxicity, diabetes, dyslipidemia, hypertension. Therefore, the 
recommendation is to avoid excessive immunosuppression. 
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In some cases in which a post-transplant neoplasm has developed, changes in 
immunosuppression may be considered with a potential effect on subsequent 
evolution. In patients with Kaposi's sarcoma, substitution of ICN by mTORi favorably 
influences the disease. On the other hand, the reduction of immunosuppressive 
potency in patients with post-transplant lymphoma was associated with better 
evolution. 
 
In patients with cutaneous non-melanoma tumors, substitution of CNI by mTORi 
reduces the risk of developing a second neoplasm. However, this change in 
immunosuppression is not considered justified since these tumors do not pose a vital 
risk to the patient. 
 
Although the weakness of the scientific evidence does not allow for a 
recommendation, in clinical practice it is common to substitute CNI for patients who 
have had a non-cutaneous neoplasia. When this strategy is used, possible interference 
with antineoplastic treatment should be taken into account, since mTORi can increase 
the medullary aplasia caused by chemotherapy. On the other hand, since they inhibit 
scarring they can lead to complications in case of surgical treatment. 
 
Considering there are no statistical significance in some cancer because of 
the little number of patients, we have made the Kaplan-Meier test with all patients 
with de novo neoplasia. The test has shown that mTORi and MMF are better than CNI. 
In the short-term, MMF is similar with CNI, and mTORi is better than others two. In the 
middle-term, the MMF is the best in these 3 inhinitor, however, later than 80 months, 
the effect of MMF is worse than mTORi. Obviously, CNI is the worst in these 3. 
Compare in two inhibitor of mTORi. Due to the Kaplan-Meier test (with the p=0.042), 
the effect of Everolimus is better than Sirolimus. And theirs different is about 10%. 
There are some articles indicate de novo neoplasia is a very significant cause of 
mortality, particularly for long-term survivors, and minimization of long-term 
immunosuppression should be aimed at reducing the incidence of de novo neoplasia. 
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There is growing evidence that the incidence of neoplastic disease is inferior in patients 
with gradual reduction of CNI with the introduction of mTOR inhibitors, vs those 
subjects treated with standard-dose CNI. 
 
There are few articles talking about mTORi treatment in liver transplant patients 
with neoplasia de novo124. 
 
 
mTORi in digestive system cancer 
 
We have associated in this cancer all colorectal, gastric and esophagus tumors 
(n=14). In test survival (Kaplan-Meier), the mTORi’s effect is the best of the 3 drugs 
we study (CNI, mTORi, MMF), and the survival without CNI is better than with CNI, 
although p>0,05 probably associated to the litte sample size. 
 
Compared the patients use Everolimus and Sirolimus, there is 1 patient use 
Everolimus, and cannot present the different clearly. There are no articles talking about 
mTORi treatment in liver transplant patients with digestive system tumors. 
 
mTORi in Skin cancer 
 
For the skin cancer, we have not found differences in survival depending of type of 
immunosuppressant therapy. In the first 50 months, the MMF is better than others two 
(n=55, survival 100% vs 88% and 80%, p=0.954); between the 75 months and 120 
months, the CNI is better than others(82% vs 77% and 70%); and after 120 months, 
the mTORi shown better effect. In the short-term (about 50 months). Also, there is no 
differences between everolimus and sirolimus (n=22, p=0.866, survival 88% vs 78%). 
About CNI, with and without it are not obvious, after 150 months, without CNI’s rate is 
higher than other. Without steroid therapy is much better than patient with the steroid 
therapy. Considering the stage of skin cancer and the early diagnosis, the treatment 
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method always be resection. The survival time is better than the non-skin cancer. And 
many articles indicate they get the same results125. 
 
mTORi in Otorhinolaryngologic cancer 
 
We have made the survival test to check the inhibitor’s efficacy in ORL cancer and 
get the result. The resection is the best treatment method for liver transplant patients 
with Otorhinolaryngologic cancer (n=31, p=0.03). MMF treatment is better than mTORi 
and CNI in prolong the survival of these patients (p<0.05). Also, mTORi is better than 
CNI. Without CNI’s therapy is better than CNI therapy (p=0.018). The effect of 
Everolimus seems to be better than Sirolimus (n=16, p=0.159). Because there is no 
patients with Steroid therapy, it cannot present the difference of with or without it. And 
the results as I expected that Everolimus with the best effective in all inhibitors in our 
study. May it related the Everolimus is the second generation mTORi. There is no 
articles talking about this fact in liver transplant patients with ORL cancer. 
 
mTORi in Lung cancer 
 
In our study, the most of patients (14 patients) with novo lung cancer is in advanced 
stage, only 5 patients to meet the conditions of resection. Although the number of 
patients with resection is less than others, for the survival time, resection is the best 
treatment method to solution cancer. About inhibitors, mTORi is better than others 2 
drugs CNI and MMF(p=0.067), CNI and MMF are not different clearly although CNI is 
a little better, and the survival time is largest that almost reach 50 months. In the first 
15 months, without CNI therapy is better than CNI therapy. So, with and without CNI 
therapy are not different clearly. Sirolimus has no a good effective when we compared 
Sirolimus and Everolimus. As we mentioned in result chapter, in the survival time,  
everolimus therapy is more than 2 times than patients with sirolimus. Due to the 
developing of lung cancer is fast, the survival is less than 50 months. 
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mTORi in lymphoproliferative syndrome 
 
The mTORi is the best of these 3 inhibitor (p=0.185), although the largest survival 
time (more than 140 months) is by patient with CNI. And only 1 patient use MMF. The 
survival rate of without CNI therapy is better than with it. There is only one patient with 
steroid therapy, so we cannot conclude anything. There are 7 patients use the mTORi 
and the efficacy of Everolimus seems to be better than Sirolimus.  
 
In the last 5 patients with SLPT we have treated these patients with mTORi and 
rituximab, with great results124. 
 
There are no articles talking about mTORi treatment in liver transplant patients 
with SLPT 
 
 
mTORi in Breast cancer 
 
There are 6 patients with breast cancer, 1 patient with CNI therapy, 3 patients with 
MMF therapy and 3 patients with mTORi therapy. In the survival test, the MMF and 
mTORi are similar, but MMF is better. The 6 patients without steroid therapy and all 
the 3 patients with mTORi were treated with Sirolimus. In our study, all patients with 
novo breast cancer were resection. Due to the limitation of data and result, the analysis 
dose not statistical significance. 
 
mTORi in Urinary system cancer 
 
In the survival test, the survival is better with mTORi (n=9) is the best, MMF (n=4) 
is between mTORi and CNI (n=5). In the short-term (50 months), with CNI therapy is 
better, and after 50 months, without CNI therapy is better and the different is almost 
40%. There are 2 patients with Everolimus and 7 patients with Sirolimus. In this survival 
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test, the survival rate of patients with Everolimus is better than Sirolimus. Like the result 
present that survival of CNI reach 50 months and the mTORi reach almost 200 months. 
Everolimus seems to be also the best treatment for these patients.  
 
mTORi in Hepatobiliary cancer 
 
Excepting HCC, studied apart, we analyze the others hepatobiliary cancers such 
as pancreatic cancer, hepatic sarcoma and cholangiocarcinoma. There are 4 patients 
with hepatobiliary cancer. And in these patients, 3 patients with CNI and 1 with mTORi 
(Sirolimus). In this survival test, CNI’s effective is better and reach 9 months, Sirolimus 
reach 3 months, but the sample size is too short to get some conclusion. 
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7. Conclusions 
 
 
1. Tobacco and Alcohol reduce the survival of patients after OLT in HCC and de novo 
neoplasia. 
 
2. Vascular and capsular invasion and advanced Edmondson stage reduce the 
survival of patients transplanted because of HCC 
 
3. mTORi immunosuppression, specially everolimus, increase the survival of patients 
after OLT in HCC compared to CNI. 
 
4. Recurrence of HCC is not associated to treatment with CNII or mTORi 
 
5. For the solid cancer, resection increase the survival of patients OLT with neoplasia 
de novo compared to no treatment or chemotherapy/radiotherapy. 
 
6. TNM and tumoral stage are good predictors of survival in patients with neoplasia 
de novo. 
 
7. mTORi immunosuppression, specially everolimus, increase the survival of patients 
after OLT in de novo neoplasia compared to CNI, above all in ORL cancer, lung 
cancer, SLPT, digestive cancer, breast cancer and urinary cancer. 
 
8. Recurrence of neoplasia de novo is associated to treatment with CNI in ORL 
cancer, lung cancer, gastric cancer and kidney cancer. 
 
9. This benifit of mTORi cannot be applied to skin cancer and HBP cancer. 
 
10. MMF monotherapy also increase survival in ORL and breast cancer. 
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